CATH Search:   
       by CATH code, keyword
QuickSearch:   
by PDB,NDB,UniProt,PROSITE Code or Search Term(s)  
(use 'Shift Left-Click' to collapse/expand all levels downwards; use 'Control Left-Click' to collapse/expand all levels upwards)
 
(-)
Class: Mainly Beta (13760)
(-)
Architecture: Sandwich (5577)
(-)
Topology: Immunoglobulin-like (3897)
(-)
Homologous Superfamily: Immunoglobulins (2282)
(-)
Human (Homo sapiens) (912)
1A1MB:1-99; A:182-272MHC CLASS I MOLECULE B*5301 COMPLEXED WITH PEPTIDE TPYDINQML FROM GAG PROTEIN OF HIV2
1A1NB:1-99; A:182-272MHC CLASS I MOLECULE B*3501 COMPLEXED WITH PEPTIDE VPLRPMTY FROM THE NEF PROTEIN (75-82) OF HIV1
1A1OB:1-99; A:182-272MHC CLASS I MOLECULE B*5301 COMPLEXED WITH PEPTIDE LS6 (KPIVQYDNF) FROM THE MALARIA PARASITE P. FALCIPARUM
1A22B:332-432; B:233-331HUMAN GROWTH HORMONE BOUND TO SINGLE RECEPTOR
1A6AA:82-180; B:94-191THE STRUCTURE OF AN INTERMEDIATE IN CLASS II MHC MATURATION: CLIP BOUND TO HLA-DR3
1A6ZB:1-99; D:1-99; A:183-273; C:183-273HFE (HUMAN) HEMOCHROMATOSIS PROTEIN
1A8JH:2-111; L:2-111; H:112-212; L:112-212IMMUNOGLOBULIN LAMBDA LIGHT CHAIN DIMER (MCG) COMPLEX WITH ASPARTAME
1A9BB:1-100; E:1-100; A:182-272; D:182-272DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B3501 DUE TO NONSTANDARD POSITIONING OF THE C-TERMINUS
1A9EB:1-100; A:182-272DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B3501 DUE TO NONSTANDARD POSITIONING OF THE C-TERMINUS
1AD0A:108-210; B:114-211; D:114-211; B:1-113; D:1-113; C:108-210; A:1-107; C:1-107FAB FRAGMENT OF ENGINEERED HUMAN MONOCLONAL ANTIBODY A5B7
1AD9A:108-208; B:114-212; H:114-212; B:1-113; H:1-113; L:107-210; L:1-106; A:1-107IGG-FAB FRAGMENT OF ENGINEERED HUMAN MONOCLONAL ANTIBODY CTM01
1ADQA:338-443; L:2-107; L:108-211; A:238-337; H:1-113; H:114-223BCRYSTAL STRUCTURE OF A HUMAN IGM RHEUMATOID FACTOR FAB IN COMPLEX WITH ITS AUTOANTIGEN IGG FC
1AGBB:1-99; A:182-272ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGRKKYKL-3R MUTATION)
1AGCB:1-99; A:182-272ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYQL-7Q MUTATION)
1AGDB:1-99; A:182-272ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYKL-INDEX PEPTIDE)
1AGEB:1-99; A:182-272ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYRL-7R MUTATION)
1AGFB:1-99; A:182-272ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKRYKL-5R MUTATION)
1AH1A:1A-131CTLA-4, NMR, 20 STRUCTURES
1AKJB:2-99; A:182-270; D:1-114; E:1-114COMPLEX OF THE HUMAN MHC CLASS I GLYCOPROTEIN HLA-A2 AND THE T CELL CORECEPTOR CD8
1AO7B:0-99; A:182-270; E:3-117; E:118-243; D:1-121COMPLEX BETWEEN HUMAN T-CELL RECEPTOR, VIRAL PEPTIDE (TAX), AND HLA-A 0201
1AQDA:82-181; D:82-179; G:82-179; J:82-179; K:93-191; B:93-190; E:93-190; H:93-190HLA-DR1 (DRA, DRB1 0101) HUMAN CLASS II HISTOCOMPATIBILITY PROTEIN (EXTRACELLULAR DOMAIN) COMPLEXED WITH ENDOGENOUS PEPTIDE
1AQKH:124-223; L:2-111; L:112-212; H:2-123THREE-DIMENSIONAL STRUCTURE OF A HUMAN FAB WITH HIGH AFFINITY FOR TETANUS TOXOID
1AR2A:1-109DISULFIDE-FREE IMMUNOGLOBULIN FRAGMENT
1AXIB:132-232; B:32-131STRUCTURAL PLASTICITY AT THE HGH:HGHBP INTERFACE
1B0GB:0-99; A:182-270; D:182-270; E:0-99CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A2.1)/BETA 2-MICROGLOBULIN/PEPTIDE P1049 COMPLEX
1B0RB:400-499; A:182-270CRYSTAL STRUCTURE OF HLA-A*0201 COMPLEXED WITH A PEPTIDE WITH THE CARBOXYL-TERMINAL GROUP SUBSTITUTED BY A METHYL GROUP
1B0WA:1-108; B:1-108; C:1-108STRUCTURAL COMPARISON OF AMYLOIDOGENIC LIGHT CHAIN DIMER IN TWO CRYSTAL FORMS WITH NONAMYLOIDOGENIC COUNTERPARTS
1B3JA:181-274STRUCTURE OF THE MHC CLASS I HOMOLOG MIC-A, A GAMMADELTA T CELL LIGAND
1B4JL:108-211; L:1-107; H:2-117; H:118-217COMPARISON OF THE THREE-DIMENSIONAL STRUCTURES OF A HUMANIZED AND A CHIMERIC FAB OF AN ANTI-GAMMA-INTERFERON ANTIBODY
1B6DA:108-211; B:108-211; A:1-107; B:1-107BENCE JONES PROTEIN DEL: AN ENTIRE IMMUNOGLOBULIN KAPPA LIGHT-CHAIN DIMER
1B6UA:103-203; A:5-102CRYSTAL STRUCTURE OF THE HUMAN KILLER CELL INHIBITORY RECEPTOR (KIR2DL3) SPECIFIC FOR HLA-CW3 RELATED ALLELES
1BBJA:109-211; B:115-212; H:115-212; L:109-211; B:2-114; H:2-114; A:1-108; L:1-108CRYSTAL STRUCTURE OF A CHIMERIC FAB' FRAGMENT OF AN ANTIBODY BINDING TUMOUR CELLS
1BD2B:1-99; A:182-270; E:3-118; D:117-201; E:119-244; D:1-116COMPLEX BETWEEN HUMAN T-CELL RECEPTOR B7, VIRAL PEPTIDE (TAX) AND MHC CLASS I MOLECULE HLA-A 0201
1BEYL:109-211; H:122-219; H:1-121; L:1-108ANTIBODY TO CAMPATH-1H HUMANIZED FAB
1BJ8A:1-109THIRD N-TERMINAL DOMAIN OF GP130, NMR, MINIMIZED AVERAGE STRUCTURE
1BJMA:2-111; B:2-111; A:112-212; B:112-212LOC NAKS, A LAMBDA 1 TYPE LIGHT-CHAIN DIMER (BENCE-JONES PROTEIN) CRYSTALLIZED IN NAKSO4
1BOYA:3-105; A:106-213EXTRACELLULAR REGION OF HUMAN TISSUE FACTOR
1BP3B:202-301; B:302-404THE XRAY STRUCTURE OF A GROWTH HORMONE-PROLACTIN RECEPTOR COMPLEX
1BPVA:0-103TITIN MODULE A71 FROM HUMAN CARDIAC MUSCLE, NMR, 50 STRUCTURES
1BQSA:91-209; A:1-90THE CRYSTAL STRUCTURE OF MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1)
1BQUA:105-214; B:105-213; A:5-104; B:5-104CYTOKYNE-BINDING REGION OF GP130
1BREA:1-107; B:1-107; C:1-107; D:1-107; E:1-107; F:1-107IMMUNOGLOBULIN LIGHT CHAIN PROTEIN
1BVKA:1-108; B:1-116; E:1-116; D:1-108HUMANIZED ANTI-LYSOZYME FV COMPLEXED WITH LYSOZYME
1BWWA:1-109; B:1-109BENCE-JONES IMMUNOGLOBULIN REI VARIABLE PORTION, T39K MUTANT
1BX2A:82-181; D:82-181; B:92-193; E:92-191CRYSTAL STRUCTURE OF HLA-DR2 (DRA*0101,DRB1*1501) COMPLEXED WITH A PEPTIDE FROM HUMAN MYELIN BASIC PROTEIN
1C8PA:1-102NMR STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE COMMON BETA-CHAIN IN THE GM-CSF, IL-3 AND IL-5 RECEPTORS
1CCZA:1-93; A:94-171CRYSTAL STRUCTURE OF THE CD2-BINDING DOMAIN OF CD58 (LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN 3) AT 1.8-A RESOLUTION
1CD0B:1-107; A:1-108STRUCTURE OF HUMAN LAMDA-6 LIGHT CHAIN DIMER JTO
1CD8A:1-114CRYSTAL STRUCTURE OF A SOLUBLE FORM OF THE HUMAN T CELL CO-RECEPTOR CD8 AT 2.6 ANGSTROMS RESOLUTION
1CD9D:2-108; B:1-108; B:109-213; D:109-2122:2 COMPLEX OF G-CSF WITH ITS RECEPTOR
1CDBA:1-105STRUCTURE OF THE GLYCOSYLATED ADHESION DOMAIN OF HUMAN T LYMPHOCYTE GLYCOPROTEIN CD2
1CDHA:1-98; A:99-173STRUCTURES OF AN HIV AND MHC BINDING FRAGMENT FROM HUMAN CD4 AS REFINED IN TWO CRYSTAL LATTICES
1CDIA:1-98; A:99-173STRUCTURES OF AN HIV AND MHC BINDING FRAGMENT FROM HUMAN CD4 AS REFINED IN TWO CRYSTAL LATTICES
1CDJA:1-98; A:99-173STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4
1CDUA:1-98; A:99-173STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4 MUTANT WITH PHE 43 REPLACED BY VAL
1CDYA:1-98; A:99-173STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4 MUTANT WITH GLY 47 REPLACED BY SER
1CG9B:1-100; A:182-272COMPLEX RECOGNITION OF THE SUPERTYPIC BW6-DETERMINANT ON HLA-B AND-C MOLECULES BY THE MONOCLONAL ANTIBODY SFR8-B6
1CI5A:1-95GLYCAN-FREE MUTANT ADHESION DOMAIN OF HUMAN CD58 (LFA-3)
1CN4A:119-220; B:119-220; A:22-118; B:22-118ERYTHROPOIETIN COMPLEXED WITH EXTRACELLULAR DOMAINS OF ERYTHROPOIETIN RECEPTOR
1CVSC:149-249; D:149-249; C:250-359; D:250-358CRYSTAL STRUCTURE OF A DIMERIC FGF2-FGFR1 COMPLEX
1CZ8L:109-211; H:124-223; Y:124-223; H:1-123; Y:1-123; X:109-211; L:1-108; X:1-108VASCULAR ENDOTHELIAL GROWTH FACTOR IN COMPLEX WITH AN AFFINITY MATURED ANTIBODY
1D5MA:82-181; B:92-190X-RAY CRYSTAL STRUCTURE OF HLA-DR4 COMPLEXED WITH PEPTIDE AND SEB
1D5XA:82-181; B:92-190X-RAY CRYSTAL STRUCTURE OF HLA-DR4 COMPLEXED WITH DIPEPTIDE MIMETIC AND SEB
1D5ZA:82-180; B:92-190X-RAY CRYSTAL STRUCTURE OF HLA-DR4 COMPLEXED WITH PEPTIDOMIMETIC AND SEB
1D6EA:82-180; B:92-190CRYSTAL STRUCTURE OF HLA-DR4 COMPLEX WITH PEPTIDOMIMETIC AND SEB
1DANU:91-210; T:6-80COMPLEX OF ACTIVE SITE INHIBITED HUMAN BLOOD COAGULATION FACTOR VIIA WITH HUMAN RECOMBINANT SOLUBLE TISSUE FACTOR
1DCLA:1-111; B:1-111; A:112-212; B:112-212MCG, A LAMBDA V TYPE LIGHT-CHAIN DIMER (BENCE-JONES PROTEIN), CRYSTALLIZED FROM AMMONIUM SULFATE
1DE4B:1-99; E:1-99; H:1-99; A:183-273; D:183-273; G:183-273HEMOCHROMATOSIS PROTEIN HFE COMPLEXED WITH TRANSFERRIN RECEPTOR
1DEEC:1109-1211; B:501-621; D:1501-1621; F:2501-2621; B:622-723; D:1622-1723; F:2622-2723; A:108-211; E:2108-2211; A:1-107; E:2001-2107; C:1001-1108CRYSTAL STRUCTURE AT 2.7A RESOLUTION OF A COMPLEX BETWEEN A STAPHYLOCOCCUS AUREUS DOMAIN AND A FAB FRAGMENT OF A HUMAN IGM ANTIBODY
1DFBL:108-209; H:127-226; H:1-126; L:1-106STRUCTURE OF A HUMAN MONOCLONAL ANTIBODY FAB FRAGMENT AGAINST GP41 OF HUMAN IMMUNODEFICIENCY VIRUS TYPE I
1DJSA:147-250; A:251-362LIGAND-BINDING PORTION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 IN COMPLEX WITH FGF1
1DL7L:1-109; H:1-112THE STRUCTURAL BASIS OF REPERTOIRE SHIFT IN AN IMMUNE RESPONSE TO PHOSPHOCHOLINE
1DLHA:82-181; D:82-181; B:93-190; E:93-190CRYSTAL STRUCTURE OF THE HUMAN CLASS II MHC PROTEIN HLA-DR1 COMPLEXED WITH AN INFLUENZA VIRUS PEPTIDE
1DN0A:110-212; A:1-109; C:1-109; B:1-120; D:1-120; D:121-222; B:121-222; C:110-212STRUCTURE OF THE FAB FRAGMENT FROM A HUMAN IGM COLD AGGLUTININ
1DN2A:338-443; B:338-443; A:238-337; B:238-337FC FRAGMENT OF HUMAN IGG1 IN COMPLEX WITH AN ENGINEERED 13 RESIDUE PEPTIDE DCAWHLGELVWCT-NH2
1DQLL:1-106; H:2-123CRYSTAL STRUCTURE OF AN UNLIGANDED (NATIVE) FV FROM A HUMAN IGM ANTI-PEPTIDE ANTIBODY
1DR9A:1-105; A:106-200CRYSTAL STRUCTURE OF A SOLUBLE FORM OF B7-1 (CD80)
1DUYB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF HLA-A*0201/OCTAMERIC TAX PEPTIDE COMPLEX
1DUZB:0-99; E:0-99; A:182-270; D:182-270HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A 0201) IN COMPLEX WITH A NONAMERIC PEPTIDE FROM HTLV-1 TAX PROTEIN
1E0OB:149-250; D:149-250; B:251-359; D:251-359CRYSTAL STRUCTURE OF A TERNARY FGF1-FGFR2-HEPARIN COMPLEX
1E27B:1-99; A:182-272NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED WITH HIV IMMUNODOMINANT EPITOPE KM1(LPPVVAKEI)
1E28B:1-99; A:182-272NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED WITH HIV IMMUNODOMINANT EPITOPE KM2(TAFTIPSI)
1E4JA:87-172; A:2-86CRYSTAL STRUCTURE OF THE SOLUBLE HUMAN FC-GAMMA RECEPTOR III
1E4KA:338-443; B:338-443; A:238-337; B:238-337; C:87-172; C:2-86CRYSTAL STRUCTURE OF SOLUBLE HUMAN IGG1 FC FRAGMENT-FC-GAMMA RECEPTOR III COMPLEX
1EAJB:20-139; A:16-139DIMERIC STRUCTURE OF THE COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR D1 DOMAIN AT 1.35 ANGSTROM RESOLUTION
1EBAA:119-220; B:119-218; A:22-118; B:22-118COMPLEX BETWEEN THE EXTRACELLULAR DOMAIN OF ERYTHROPOIETIN (EPO) RECEPTOR [EBP] AND AN INACTIVE PEPTIDE [EMP33] CONTAINS 3,5-DIBROMOTYROSINE IN POSITION 4 (DENOTED DBY)
1EBPA:119-220; B:119-220; A:22-118; B:22-118COMPLEX BETWEEN THE EXTRACELLULAR DOMAIN OF ERYTHROPOIETIN (EPO) RECEPTOR [EBP] AND AN AGONIST PEPTIDE [EMP1]
1EEQA:1-107; B:301-407M4L/Y(27D)D/T94H MUTANT OF LEN
1EERB:119-220; C:119-220; C:22-118; B:24-118CRYSTAL STRUCTURE OF HUMAN ERYTHROPOIETIN COMPLEXED TO ITS RECEPTOR AT 1.9 ANGSTROMS
1EEUA:1-106; B:301-407M4L/Y(27D)D/Q89D/T94H MUTANT OF LEN
1EEYB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE DETERMINATION OF HLA A2 COMPLEXED TO PEPTIDE GP2 WITH THE SUBSTITUTION (I2L/V5L/L9V)
1EEZB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE DETERMINATION OF HLA-A2.1 COMPLEXED TO GP2 PEPTIDE VARIANT(I2L/V5L)
1EFQA:1-107Q38D MUTANT OF LEN
1EFXB:0-99; A:182-272; D:103-200; E:103-200; D:5-102; E:5-102STRUCTURE OF A COMPLEX BETWEEN THE HUMAN NATURAL KILLER CELL RECEPTOR KIR2DL2 AND A CLASS I MHC LIGAND HLA-CW3
1EGJL:109-211; L:1-108; H:114-223; H:1-113; A:338-438DOMAIN 4 OF THE BETA COMMON CHAIN IN COMPLEX WITH AN ANTIBODY
1EK3A:1-108; B:301-408KAPPA-4 IMMUNOGLOBULIN VL, REC
1ERNB:119-220; A:119-218; A:19-118; B:19-118NATIVE STRUCTURE OF THE EXTRACELLULAR DOMAIN OF ERYTHROPOIETIN (EPO) RECEPTOR [EBP]
1EV2E:150-250; F:150-250; G:151-250; H:151-250; H:251-357; G:251-357; F:251-357; E:251-357CRYSTAL STRUCTURE OF FGF2 IN COMPLEX WITH THE EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 2 (FGFR2)
1EVTC:149-249; D:149-249; D:250-357; C:250-357CRYSTAL STRUCTURE OF FGF1 IN COMPLEX WITH THE EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 1 (FGFR1)
1EVUA:517-630; B:517-630; A:631-725; B:631-725; A:8-192; B:8-192HUMAN FACTOR XIII WITH CALCIUM BOUND IN THE ION SITE
1EX0A:517-630; B:517-630; A:631-725; B:631-725; A:8-192; B:8-192HUMAN FACTOR XIII, MUTANT W279F ZYMOGEN
1EXUB:1-99; A:176-266CRYSTAL STRUCTURE OF THE HUMAN MHC-RELATED FC RECEPTOR
1F13A:516-630; B:516-630; A:631-727; B:631-727; B:8-192; A:8-192RECOMBINANT HUMAN CELLULAR COAGULATION FACTOR XIII
1F2QA:4-84; A:85-174CRYSTAL STRUCTURE OF THE HUMAN HIGH-AFFINITY IGE RECEPTOR
1F42A:103-210; A:1-84; A:214-304THE P40 DOMAIN OF HUMAN INTERLEUKIN-12
1F45A:103-210; A:1-84; A:214-302HUMAN INTERLEUKIN-12
1F5WB:19-139; A:16-139DIMERIC STRUCTURE OF THE COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR D1 DOMAIN
1F6AB:436-543; D:436-543; A:4-84; B:336-435; D:336-435; A:85-173STRUCTURE OF THE HUMAN IGE-FC BOUND TO ITS HIGH AFFINITY RECEPTOR FC(EPSILON)RI(ALPHA)
1F6LL:1-106VARIABLE LIGHT CHAIN DIMER OF ANTI-FERRITIN ANTIBODY
1FAKT:6-105; T:106-206HUMAN TISSUE FACTOR COMPLEXED WITH COAGULATION FACTOR VIIA INHIBITED WITH A BPTI-MUTANT
1FC1A:338-443; B:338-443; A:238-337; B:238-337CRYSTALLOGRAPHIC REFINEMENT AND ATOMIC MODELS OF A HUMAN FC FRAGMENT AND ITS COMPLEX WITH FRAGMENT B OF PROTEIN A FROM STAPHYLOCOCCUS AUREUS AT 2.9-AND 2.8-ANGSTROMS RESOLUTION
1FCCA:338-443; B:338-443; A:238-337; B:238-337CRYSTAL STRUCTURE OF THE C2 FRAGMENT OF STREPTOCOCCAL PROTEIN G IN COMPLEX WITH THE FC DOMAIN OF HUMAN IGG
1FCGA:90-174; A:4-89ECTODOMAIN OF HUMAN FC GAMMA RECEPTOR, FCGRIIA
1FE8L:108-211; H:116-214; I:116-214; J:116-214; H:1-115; I:1-115; J:1-115; M:108-211; N:109-211; L:1-107; M:1-107; N:1-108CRYSTAL STRUCTURE OF THE VON WILLEBRAND FACTOR A3 DOMAIN IN COMPLEX WITH A FAB FRAGMENT OF IGG RU5 THAT INHIBITS COLLAGEN BINDING
1FG9D:109-220; E:109-219; C:109-224; C:12-108; D:12-108; E:13-1083:1 COMPLEX OF INTERFERON-GAMMA RECEPTOR WITH INTERFERON-GAMMA DIMER
1FH5L:110-212; H:121-213; H:4-120; L:2-109CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF THE MONOCLONAL ANTIBODY MAK33
1FIEA:516-630; B:516-630; A:631-725; B:631-724; A:9-192; B:10-192RECOMBINANT HUMAN COAGULATION FACTOR XIII
1FLTX:132-226; Y:132-225VEGF IN COMPLEX WITH DOMAIN 2 OF THE FLT-1 RECEPTOR
1FNAA:6-96CRYSTAL STRUCTURE OF THE TENTH TYPE III CELL ADHESION MODULE OF HUMAN FIBRONECTIN
1FNFA:1416-1508; A:1142-1235; A:1327-1415; A:1239-1325FRAGMENT OF HUMAN FIBRONECTIN ENCOMPASSING TYPE-III REPEATS 7 THROUGH 10
1FNHA:3-92; A:93-182; A:183-271CRYSTAL STRUCTURE OF HEPARIN AND INTEGRIN BINDING SEGMENT OF HUMAN FIBRONECTIN
1FNLA:90-175; A:5-89CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF A HUMAN FCGRIII
1FP5A:436-543; A:336-435CRYSTAL STRUCTURE ANALYSIS OF THE HUMAN IGE-FC CEPSILON3-CEPSILON4 FRAGMENT.
1FQ9C:149-249; D:149-249; C:250-359; D:250-358CRYSTAL STRUCTURE OF A TERNARY FGF2-FGFR1-HEPARIN COMPLEX
1FV1A:82-181; D:82-181; B:93-190; E:93-190STRUCTURAL BASIS FOR THE BINDING OF AN IMMUNODOMINANT PEPTIDE FROM MYELIN BASIC PROTEIN IN DIFFERENT REGISTERS BY TWO HLA-DR2 ALLELES
1FVCC:1-108; B:1-120; D:1-120; A:1-109X-RAY STRUCTURES OF THE ANTIGEN-BINDING DOMAINS FROM THREE VARIANTS OF HUMANIZED ANTI-P185-HER2 ANTIBODY 4D5 AND COMPARISON WITH MOLECULAR MODELING
1FVDA:109-211; B:121-220; D:121-220; B:1-120; D:1-120; C:109-211; A:1-108; C:1-108X-RAY STRUCTURES OF THE ANTIGEN-BINDING DOMAINS FROM THREE VARIANTS OF HUMANIZED ANTI-P185-HER2 ANTIBODY 4D5 AND COMPARISON WITH MOLECULAR MODELING
1FVEA:109-211; B:121-220; D:121-220; B:1-120; D:1-120; C:109-211; A:1-108; C:1-108X-RAY STRUCTURES OF THE ANTIGEN-BINDING DOMAINS FROM THREE VARIANTS OF HUMANIZED ANTI-P185-HER2 ANTIBODY 4D5 AND COMPARISON WITH MOLECULAR MODELING
1FYHB:109-222; E:109-221; B:12-108; E:12-1081:1 COMPLEX BETWEEN AN INTERFERON GAMMA SINGLE-CHAIN VARIANT AND ITS RECEPTOR
1FYTE:3-118; D:117-202; A:82-181; E:119-246; B:93-190; D:1-116CRYSTAL STRUCTURE OF A COMPLEX OF A HUMAN ALPHA/BETA-T CELL RECEPTOR, INFLUENZA HA ANTIGEN PEPTIDE, AND MHC CLASS II MOLECULE, HLA-DR1
1G0XA:97-198; A:2-96CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF LIR-1 (ILT2)
1G0YR:98-203; R:204-315; R:6-97IL-1 RECEPTOR TYPE 1 COMPLEXED WITH ANTAGONIST PEPTIDE AF10847
1G1CA:2-99; B:2-99I1 DOMAIN FROM TITIN
1G84A:1-105THE SOLUTION STRUCTURE OF THE C EPSILON2 DOMAIN FROM IGE
1GGTA:516-630; B:516-630; A:631-729; B:631-725; A:8-192; B:8-192THREE-DIMENSIONAL STRUCTURE OF A TRANSGLUTAMINASE: HUMAN BLOOD COAGULATION FACTOR XIII
1GGUA:517-630; B:517-630; A:631-724; B:631-724; A:8-192; B:8-192HUMAN FACTOR XIII WITH CALCIUM BOUND IN THE ION SITE
1GGYA:517-630; B:517-630; A:631-724; B:631-724; A:8-192; B:8-192HUMAN FACTOR XIII WITH YTTERBIUM BOUND IN THE ION SITE
1GH7A:109-215; B:109-215; A:320-416; B:320-416; A:1-95; B:1-95; A:218-308; B:218-308CRYSTAL STRUCTURE OF THE COMPLETE EXTRACELLULAR DOMAIN OF THE BETA-COMMON RECEPTOR OF IL-3, IL-5, AND GM-CSF
1GSMA:91-206; A:1-90A REASSESSMENT OF THE MADCAM-1 STRUCTURE AND ITS ROLE IN INTEGRIN RECOGNITION.
1GXEA:1-130CENTRAL DOMAIN OF CARDIAC MYOSIN BINDING PROTEIN C
1GYAA:1-105N-GLYCAN AND POLYPEPTIDE NMR SOLUTION STRUCTURES OF THE ADHESION DOMAIN OF HUMAN CD2
1GZPB:0-99; A:183-278CD1B IN COMPLEX WITH GM2 GANGLIOSIDE
1GZQB:0-99; A:183-278CD1B IN COMPLEX WITH PHOPHATIDYLINOSITOL
1H0DA:108-203; A:1-107; B:114-212; B:1-113CRYSTAL STRUCTURE OF HUMAN ANGIOGENIN IN COMPLEX WITH FAB FRAGMENT OF ITS MONOCLONAL ANTIBODY MAB 26-2F
1H15A:82-181; D:82-181; B:93-190; E:93-190X-RAY CRYSTAL STRUCTURE OF HLA-DRA1*0101/DRB5*0101 COMPLEXED WITH A PEPTIDE FROM EPSTEIN BARR VIRUS DNA POLYMERASE
1H3TA:338-443; B:338-433; A:238-337; B:238-337CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (MN2F)2
1H3UA:338-443; B:338-443; A:238-337; B:238-337CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (M3N2F)2
1H3VA:338-443; B:338-443; A:238-337; B:238-337CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (G2F)2,SG P212121
1H3WM:338-443; M:238-337STRUCTURAL ANALYSIS OF HUMAN IGG-FC GLYCOFORMS REVEALS A CORRELATION BETWEEN GLYCOSYLATION AND STRUCTURAL INTEGRITY
1H3XA:338-443; B:338-443; A:238-337; B:239-337CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (G0F)2
1H9VA:87-171; A:1-86HUMAN FC-GAMMA-RECEPTOR IIA (FCGRIIA), MONOCLINIC
1HCFX:283-383; Y:283-383CRYSTAL STRUCTURE OF TRKB-D5 BOUND TO NEUROTROPHIN-4/5
1HDMB:87-185; A:84-195HISTOCOMPATIBILITY ANTIGEN HLA-DM
1HE7A:282-388HUMAN NERVE GROWTH FACTOR RECEPTOR TRKA
1HEZA:108-211; B:1-121; D:1-121; D:122-222; B:122-222; C:108-211; A:1-107; C:1-107ANTIBODY-ANTIGEN COMPLEX
1HHGB:0-99; A:182-275; D:182-275; E:0-99THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
1HHHB:0-99; A:182-275THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
1HHIB:0-99; A:182-275; D:182-275; E:0-99THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
1HHJB:0-99; A:182-275; D:182-275; E:0-99THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
1HHKB:0-99; A:182-275; D:182-275; E:0-99THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
1HKFA:5-112THE THREE DIMENSIONAL STRUCTURE OF NK CELL RECEPTOR NKP44, A TRIGGERING PARTNER IN NATURAL CYTOTOXICITY
1HNFA:4-103; A:104-182CRYSTAL STRUCTURE OF THE EXTRACELLULAR REGION OF THE HUMAN CELL ADHESION MOLECULE CD2 AT 2.5 ANGSTROMS RESOLUTION
1HQRA:82-180; B:293-390CRYSTAL STRUCTURE OF A SUPERANTIGEN BOUND TO THE HIGH-AFFINITY, ZINC-DEPENDENT SITE ON MHC CLASS II
1HSAB:1-99; E:1-99; A:182-276; D:182-276THE THREE-DIMENSIONAL STRUCTURE OF HLA-B27 AT 2.1 ANGSTROMS RESOLUTION SUGGESTS A GENERAL MECHANISM FOR TIGHT PEPTIDE BINDING TO MHC
1HSBB:1-99; A:182-270DIFFERENT LENGTH PEPTIDES BIND TO HLA-AW68 SIMILARLY AT THEIR ENDS BUT BULGE OUT IN THE MIDDLE
1HWGB:132-232; C:132-232; B:32-131; C:32-1311:2 COMPLEX OF HUMAN GROWTH HORMONE WITH ITS SOLUBLE BINDING PROTEIN
1HWHB:132-232; B:32-1311:1 COMPLEX OF HUMAN GROWTH HORMONE MUTANT G120R WITH ITS SOLUBLE BINDING PROTEIN
1HXMB:126-230; D:126-230; F:126-230; H:126-230; A:1-121; C:1-121; E:1-121; G:1-121; B:1-125; D:1-125; F:1-125; H:1-125; A:122-206; C:122-206; E:122-206; G:122-206CRYSTAL STRUCTURE OF A HUMAN VGAMMA9/VDELTA2 T CELL RECEPTOR
1HXYA:82-181; B:93-190CRYSTAL STRUCTURE OF STAPHYLOCOCCAL ENTEROTOXIN H IN COMPLEX WITH HUMAN MHC CLASS II
1HYRC:181-273CRYSTAL STRUCTURE OF HUMAN MICA IN COMPLEX WITH NATURAL KILLER CELL RECEPTOR NKG2D
1HZHL:108-211; L:1-107; M:1-108; K:105-230; H:361-474; K:361-473; K:1-104; H:250-360; K:250-360; H:129-236; H:24-128; M:109-211CRYSTAL STRUCTURE OF THE INTACT HUMAN IGG B12 WITH BROAD AND POTENT ACTIVITY AGAINST PRIMARY HIV-1 ISOLATES: A TEMPLATE FOR HIV VACCINE DESIGN
1I1FB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF HUMAN CLASS I MHC (HLA-A2.1) COMPLEXED WITH BETA 2-MICROGLOBULIN AND HIV-RT VARIANT PEPTIDE I1Y
1I1RA:202-302; A:102-201; A:2-101CRYSTAL STRUCTURE OF A CYTOKINE/RECEPTOR COMPLEX
1I1YB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF HUMAN CLASS I MHC (HLA-A2.1) COMPLEXED WITH BETA 2-MICROGLOBULIN AND HIV-RT VARIANT PEPTIDE I1Y
1I4FB:0-99; A:182-270CRYSTAL STRUCTURE OF HLA-A*0201/MAGE-A4-PEPTIDE COMPLEX
1I7RB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1058
1I7TB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1049-5V
1I7UB:0-99; E:0-99; A:182-270; D:182-270CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1049-6V
1I85D:3-120; C:3-120; B:1-109; A:0-109CRYSTAL STRUCTURE OF THE CTLA-4/B7-2 COMPLEX
1I8LC:3-120; D:3-120; A:1-105; B:1-105; A:106-199; B:106-199HUMAN B7-1/CTLA-4 CO-STIMULATORY COMPLEX
1I9RL:113-215; L:1-112; M:1-112; Y:1-112; H:113-219; K:113-219; X:113-219; H:1-112; K:1-112; X:1-112; M:113-215; Y:113-215STRUCTURE OF CD40L IN COMPLEX WITH THE FAB FRAGMENT OF HUMANIZED 5C8 ANTIBODY
1IAMA:84-185; A:1-83STRUCTURE OF THE TWO AMINO-TERMINAL DOMAINS OF HUMAN INTERCELLULAR ADHESION MOLECULE-1, ICAM-1
1IARB:1-96; B:97-197INTERLEUKIN-4 / RECEPTOR ALPHA CHAIN COMPLEX
1IC1A:84-190; B:84-190; A:1-83; B:1-83THE CRYSTAL STRUCTURE FOR THE N-TERMINAL TWO DOMAINS OF ICAM-1
1IGML:1-115; H:1-129THREE DIMENSIONAL STRUCTURE OF AN FV FROM A HUMAN IGM IMMUNOGLOBULIN
1II4E:150-250; F:150-250; G:150-250; H:150-250; E:251-357; F:251-357; G:251-357; H:251-357CRYSTAL STRUCTURE OF SER252TRP APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2
1IILE:150-250; F:150-250; G:150-250; H:150-250; G:251-357; H:251-357; E:251-357; F:251-357CRYSTAL STRUCTURE OF PRO253ARG APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2
1IJ9A:90-196; A:1-89HIGHLY HYDRATED HUMAN VCAM-1 FRAGMENT
1IM3B:0-99; A:182-270; E:182-270; I:182-270; M:182-270; F:0-99; J:0-99; N:0-99CRYSTAL STRUCTURE OF THE HUMAN CYTOMEGALOVIRUS PROTEIN US2 BOUND TO THE MHC CLASS I MOLECULE HLA-A2/TAX
1IM9B:0-99; A:182-272; E:182-272; D:103-200; D:6-102; F:0-99CRYSTAL STRUCTURE OF THE HUMAN NATURAL KILLER CELL INHIBITORY RECEPTOR KIR2DL1 BOUND TO ITS MHC LIGAND HLA-CW4
1IQDA:110-211; A:2-109; B:115-210; B:1-114HUMAN FACTOR VIII C2 DOMAIN COMPLEXED TO HUMAN MONOCLONAL BO2C11 FAB.
1IRAY:95-200; Y:201-311; Y:3-94COMPLEX OF THE INTERLEUKIN-1 RECEPTOR WITH THE INTERLEUKIN-1 RECEPTOR ANTAGONIST (IL1RA)
1ITBB:98-203; B:204-315; B:6-97TYPE-1 INTERLEUKIN-1 RECEPTOR COMPLEXED WITH INTERLEUKIN-1 BETA
1J7VR:104-206; R:2-103HUMAN IL-10 / IL-10R1 COMPLEX
1J86A:4-84; B:4-84; A:85-174; B:85-173HUMAN HIGH AFFINITY FC RECEPTOR FC(EPSILON)RI(ALPHA), MONOCLINIC CRYSTAL FORM 2
1J87A:4-84; A:85-171HUMAN HIGH AFFINITY FC RECEPTOR FC(EPSILON)RI(ALPHA), HEXAGONAL CRYSTAL FORM 1
1J88A:4-84; B:4-84; C:4-84; D:4-84; E:4-84; A:85-171; B:85-171; C:85-171; D:85-171; E:85-171HUMAN HIGH AFFINITY FC RECEPTOR FC(EPSILON)RI(ALPHA), TETRAGONAL CRYSTAL FORM 1
1J8HE:3-118; D:117-202; A:82-181; E:119-246; B:92-190; D:1-116CRYSTAL STRUCTURE OF A COMPLEX OF A HUMAN ALPHA/BETA-T CELL RECEPTOR, INFLUENZA HA ANTIGEN PEPTIDE, AND MHC CLASS II MOLECULE, HLA-DR4
1J8KA:1-94NMR STRUCTURE OF THE FIBRONECTIN EDA DOMAIN, NMR, 20 STRUCTURES
1J9CT:3-105; T:106-210CRYSTAL STRUCTURE OF TISSUE FACTOR-FACTOR VIIA COMPLEX
1JE6A:184-272STRUCTURE OF THE MHC CLASS I HOMOLOG MICB
1JF1B:0-99; A:182-270CRYSTAL STRUCTURE OF HLA-A2*0201 IN COMPLEX WITH A DECAMERIC ALTERED PEPTIDE LIGAND FROM THE MART-1/MELAN-A
1JGDB:0-99; A:182-276HLA-B*2709 BOUND TO DECA-PEPTIDE S10R
1JGEB:0-99; A:182-276HLA-B*2705 BOUND TO NONA-PEPTIDE M9
1JHTB:0-99; A:182-270CRYSTAL STRUCTURE OF HLA-A2*0201 IN COMPLEX WITH A NONAMERIC ALTERED PEPTIDE LIGAND (ALGIGILTV) FROM THE MART-1/MELAN-A.
1JK8A:82-181; B:93-192CRYSTAL STRUCTURE OF A HUMAN INSULIN PEPTIDE-HLA-DQ8 COMPLEX
1JNJA:0-99NMR SOLUTION STRUCTURE OF THE HUMAN BETA2-MICROGLOBULIN
1JPSL:109-211; H:118-216; T:5-105; T:106-210; H:1-117; L:1-108CRYSTAL STRUCTURE OF TISSUE FACTOR IN COMPLEX WITH HUMANIZED FAB D3H44
1JPTL:109-211; H:118-216; H:1-117; L:1-108CRYSTAL STRUCTURE OF FAB D3H44
1JV5A:1-107; B:301-417ANTI-BLOOD GROUP A FV
1JVKA:2-112; B:2-112; A:113-213; B:113-213THREE-DIMENSIONAL STRUCTURE OF AN IMMUNOGLOBULIN LIGHT CHAIN DIMER ACTING AS A LETHAL AMYLOID PRECURSOR
1JWMA:82-181; B:93-190CRYSTAL STRUCTURE OF THE COMPLEX OF THE MHC CLASS II MOLECULE HLA-DR1(HA PEPTIDE 306-318) WITH THE SUPERANTIGEN SEC3
1JWSA:82-181; B:93-190CRYSTAL STRUCTURE OF THE COMPLEX OF THE MHC CLASS II MOLECULE HLA-DR1 (HA PEPTIDE 306-318) WITH THE SUPERANTIGEN SEC3 VARIANT 3B1
1JWUA:82-181; B:93-190CRYSTAL STRUCTURE OF THE COMPLEX OF THE MHC CLASS II MOLECULE HLA-DR1 (HA PEPTIDE 306-318) WITH THE SUPERANTIGEN SEC3 VARIANT 3B2
1K5NB:0-99; A:182-276HLA-B*2709 BOUND TO NONA-PEPTIDE M9
1KF9B:332-432; E:1332-1432; F:1632-1732; C:632-731; E:1233-1331; B:233-331; F:1533-1631; C:533-631PHAGE DISPLAY DERIVED VARIANT OF HUMAN GROWTH HORMONE COMPLEXED WITH TWO COPIES OF THE EXTRACELLULAR DOMAIN OF ITS RECEPTOR
1KFAL:114-215; H:127-225; I:127-224; L:1-113; M:1-113; I:3-121; H:2-121; M:114-213CRYSTAL STRUCTURE OF FAB FRAGMENT COMPLEXED WITH GIBBERELLIN A4
1KG0A:82-181; B:93-190STRUCTURE OF THE EPSTEIN-BARR VIRUS GP42 PROTEIN BOUND TO THE MHC CLASS II RECEPTOR HLA-DR1
1KGCD:2-116; E:3-118; D:117-206; E:119-247IMMUNE RECEPTOR
1KLGA:82-180; B:93-190CRYSTAL STRUCTURE OF HLA-DR1/TPI(23-37, THR28-->ILE MUTANT) COMPLEXED WITH STAPHYLOCOCCAL ENTEROTOXIN C3 VARIANT 3B2 (SEC3-3B2)
1KLUA:82-181; B:93-190CRYSTAL STRUCTURE OF HLA-DR1/TPI(23-37) COMPLEXED WITH STAPHYLOCOCCAL ENTEROTOXIN C3 VARIANT 3B2 (SEC3-3B2)
1KPRB:1-99; A:182-272; C:182-272; D:1-99THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E
1KTLB:1-99; A:182-272; C:182-272; D:1-99THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E
1KV3A:588-685; B:588-685; C:588-685; D:588-685; E:588-685; F:588-685; A:15-147; B:15-147; C:15-147; D:15-147; E:15-147; F:15-147; A:471-587; B:471-587; C:471-587; D:471-587; E:471-587; F:471-587HUMAN TISSUE TRANSGLUTAMINASE IN GDP BOUND FORM
1L6XA:338-443; A:238-337FC FRAGMENT OF RITUXIMAB BOUND TO A MINIMIZED VERSION OF THE B-DOMAIN FROM PROTEIN A CALLED Z34C
1L7IL:109-211; H:114-213; H:1-113; L:1-108CRYSTAL STRUCTURE OF THE ANTI-ERBB2 FAB2C4
1L9MA:595-691; B:595-691; A:480-594; B:478-594; A:1-142; B:1-142THREE-DIMENSIONAL STRUCTURE OF THE HUMAN TRANSGLUTAMINASE 3 ENZYME: BINDING OF CALCIUM IONS CHANGE STRUCTURE FOR ACTIVATION
1L9NA:595-691; B:595-691; A:481-594; B:481-594; A:1-142; B:1-142THREE-DIMENSIONAL STRUCTURE OF THE HUMAN TRANSGLUTAMINASE 3 ENZYME: BINDING OF CALCIUM IONS CHANGE STRUCTURE FOR ACTIVATION
1LDSA:0-96CRYSTAL STRUCTURE OF MONOMERIC HUMAN BETA-2-MICROGLOBULIN
1LGVA:2-112; B:2-112; A:113-213; B:113-213STRUCTURE OF A HUMAN BENCE-JONES DIMER CRYSTALLIZED IN U.S. SPACE SHUTTLE MISSION STS-95: 100K
1LHZA:2-112; B:2-112; A:113-213; B:113-213STRUCTURE OF A HUMAN BENCE-JONES DIMER CRYSTALLIZED IN U.S. SPACE SHUTTLE MISSION STS-95: 293K
1LILA:2-107; B:2-107; A:108-211; B:108-211BENCE JONES PROTEIN CLE, A LAMBDA III IMMUNOGLOBULIN LIGHT-CHAIN DIMER
1LK3L:108-210; I:120-218; H:120-217; L:1-107; M:1-107; H:1-119; I:1-119; M:108-210ENGINEERED HUMAN INTERLEUKIN-10 MONOMER COMPLEXED TO 9D7 FAB FRAGMENT
1LO5A:82-181; B:93-190CRYSTAL STRUCTURE OF THE D227A VARIANT OF STAPHYLOCOCCAL ENTEROTOXIN A IN COMPLEX WITH HUMAN MHC CLASS II
1LP9B:0-99; A:182-270; H:182-270; I:0-99; F:3-117; M:3-117; E:117-198; L:117-198; F:118-245; M:118-245; E:1-116; L:1-116XENOREACTIVE COMPLEX AHIII 12.2 TCR BOUND TO P1049/HLA-A2.1
1LQSR:104-206; S:104-206; R:2-103; S:2-103CRYSTAL STRUCTURE OF HUMAN CYTOMEGALOVIRUS IL-10 BOUND TO SOLUBLE HUMAN IL-10R1
1LVEA:1-108STRUCTURE OF THE VARIABLE DOMAIN OF HUMAN IMMUNOGLOBULIN K-4 LIGHT CHAIN LEN
1M05B:1-99; D:1-99; A:182-272; C:182-272HLA B8 IN COMPLEX WITH AN EPSTEIN BARR VIRUS DETERMINANT
1M4KA:103-200; A:8-102CRYSTAL STRUCTURE OF THE HUMAN NATURAL KILLER CELL ACTIVATOR RECEPTOR KIR2DS2 (CD158J)
1M6OB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA B*4402 IN COMPLEX WITH HLA DPA*0201 PEPTIDE
1MCCA:1-111; B:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCDA:1-111; B:1-111; B:112-216; A:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCEB:2-111; A:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCFA:1-111; B:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCHA:1-111; B:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCIA:1-111; B:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCJA:1-111; B:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCKA:1-111; B:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCNA:1-111; B:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCOH:120-221; H:328-428; L:1-111; H:1-118; L:112-212; H:223-326THREE-DIMENSIONAL STRUCTURE OF A HUMAN IMMUNOGLOBULIN WITH A HINGE DELETION
1MCQA:1-111; B:1-111; A:112-216; B:112-216PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCRA:1-111; B:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCSA:1-111; B:1-111; A:112-212; B:112-212PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS
1MCWM:2-111; W:2-112; M:112-216; W:113-216THREE-DIMENSIONAL STRUCTURE OF A HYBRID LIGHT CHAIN DIMER. PROTEIN ENGINEERING OF A BINDING CAVITY
1MHEB:1-99; A:182-272; C:182-272; D:1-99THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E
1MI5B:1-99; D:2-116; E:3-118; D:117-206; E:119-247; A:182-272THE CRYSTAL STRUCTURE OF LC13 TCR IN COMPLEX WITH HLAB8-EBV PEPTIDE COMPLEX
1MQ8A:84-184; C:84-184; A:1-83; C:1-83CRYSTAL STRUCTURE OF ALPHAL I DOMAIN IN COMPLEX WITH ICAM-1
1N0XL:108-211; L:1-107; M:1-107; K:110-230; H:110-228; H:1-109; K:1-109; M:108-211CRYSTAL STRUCTURE OF A BROADLY NEUTRALIZING ANTI-HIV-1 ANTIBODY IN COMPLEX WITH A PEPTIDE MIMOTOPE
1N26A:196-299; A:2-9,A:94-192; A:14-91CRYSTAL STRUCTURE OF THE EXTRA-CELLULAR DOMAINS OF HUMAN INTERLEUKIN-6 RECEPTOR ALPHA CHAIN
1N2RB:1-99; A:182-272A NATURAL SELECTED DIMORPHISM IN HLA B*44 ALTERS SELF, PEPTIDE REPORTOIRE AND T CELL RECOGNITION.
1N6UA:1-106; A:107-212NMR STRUCTURE OF THE INTERFERON-BINDING ECTODOMAIN OF THE HUMAN INTERFERON RECEPTOR
1N6VA:1-106; A:107-212AVERAGE STRUCTURE OF THE INTERFERON-BINDING ECTODOMAIN OF THE HUMAN TYPE I INTERFERON RECEPTOR
1N8ZA:109-211; B:121-220; B:1-120; A:1-108CRYSTAL STRUCTURE OF EXTRACELLULAR DOMAIN OF HUMAN HER2 COMPLEXED WITH HERCEPTIN FAB
1NBQA:129-233; B:129-233; A:25-128; B:26-128CRYSTAL STRUCTURE OF HUMAN JUNCTIONAL ADHESION MOLECULE TYPE 1
1NCNA:0-109; B:0-109THE RECEPTOR-BINDING DOMAIN OF HUMAN B7-2
1NCTA:-6-91TITIN MODULE M5, N-TERMINALLY EXTENDED, NMR
1NCUA:-6-91TITIN MODULE M5, N-TERMINALLY EXTENDED, NMR
1NFIA:190-292; C:190-292; B:249-355; D:249-355I-KAPPA-B-ALPHA/NF-KAPPA-B COMPLEX
1NKOA:21-147ENERGETIC AND STRUCTURAL BASIS OF SIALYLATED OLIGOSACCHARIDE RECOGNITION BY THE NATURAL KILLER CELL INHIBITORY RECEPTOR P75/AIRM1 OR SIGLEC-7
1NKRA:103-200; A:6-102INHIBITORY RECEPTOR (P58-CL42) FOR HUMAN NATURAL KILLER CELLS
1NL0H:114-214; L:1-108; L:109-209; H:1-113CRYSTAL STRUCTURE OF HUMAN FACTOR IX GLA DOMAIN IN COMPLEX OF AN INHIBITORY ANTIBODY, 10C12
1NUDA:595-691; B:595-691; A:481-594; B:481-594; A:1-142; B:1-142ROLE OF CALCIUM IONS IN THE ACTIVATION AND ACTIVITY OF THE TRANSGLUTAMINASE 3 ENZYME (3 CALCIUMS, ACTIVE FORM)
1NUFA:595-691; A:480-594; A:1-142ROLE OF CALCIUM IONS IN THE ACTIVATION AND ACTIVITY OF THE TRANSGLUTAMINASE 3 ENZYME
1NUGA:595-691; B:595-691; A:480-594; B:478-594; A:1-142; B:1-142ROLE OF CALCIUM IONS IN THE ACTIVATION AND ACTIVITY OF THE TRANSGLUTAMINASE 3 ENZYME (2 CALCIUMS, 1 MG, INACTIVE FORM)
1NUNB:151-250; B:251-355CRYSTAL STRUCTURE ANALYSIS OF THE FGF10-FGFR2B COMPLEX
1O0VB:436-545; A:436-545; A:329-435; B:329-435; A:228-328; B:228-328THE CRYSTAL STRUCTURE OF IGE FC REVEALS AN ASYMMETRICALLY BENT CONFORMATION
1O5DT:6-205DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1O7SA:24-144HIGH RESOLUTION STRUCTURE OF SIGLEC-7
1O7VA:18-144HIGH RESOLUTION STRUCTURE OF SIGLEC-7
1OF2B:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408)
1OGAB:0-99; D:3-111; E:5-115; D:112-201; E:116-244; A:182-270A STRUCTURAL BASIS FOR IMMUNODOMINANT HUMAN T-CELL RECEPTOR RECOGNITION.
1OGTB:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408)
1OHQB:1-119; A:1-120CRYSTAL STRUCTURE OF HEL4, A SOLUBLE HUMAN VH ANTIBODY DOMAIN RESISTANT TO AGGREGATION
1OL0A:1-121; B:1-121CRYSTAL STRUCTURE OF A CAMELISED HUMAN VH
1OLZA:539-628; B:539-628THE LIGAND-BINDING FACE OF THE SEMAPHORINS REVEALED BY THE HIGH RESOLUTION CRYSTAL STRUCTURE OF SEMA4D
1OM3M:109-211; H:114-227; K:114-226; H:1-113; K:1-113; L:108-211; L:2-107; M:2-108FAB 2G12 UNLIGANDED
1ONQB:1-99; D:1-99; A:183-278; C:183-278CRYSTAL STRUCTURE OF CD1A IN COMPLEX WITH A SULFATIDE
1OP3L:109-211; H:114-222; M:114-222; H:1-113; M:1-113; K:108-211; K:2-107; L:2-108CRYSTAL STRUCTURE OF FAB 2G12 BOUND TO MAN1->2MAN
1OP5K:109-208; H:114-226; M:114-226; H:1-113; M:1-113; L:108-211; L:2-107; K:2-108CRYSTAL STRUCTURE OF FAB 2G12 BOUND TO MAN9GLCNAC2
1OPGL:108-211; H:126-223; H:1-125; L:1-107OPG2 FAB FRAGMENT
1OQOA:338-443; B:338-443; A:238-337; B:238-337COMPLEX BETWEEN G0 VERSION OF AN FC BOUND TO A MINIMIZED VERSION OF PROTEIN A CALLED MINI-Z
1OQXA:338-443; B:338-443; A:238-337; B:238-337G-2 GLYCOVARIANT OF HUMAN IGG FC BOUND TO MINIMIZED VERSION OF PROTEIN A CALLED Z34C
1OVZA:100-198; B:100-192; B:5-99; A:6-99CRYSTAL STRUCTURE OF HUMAN FCARI
1OW0C:100-195; D:100-195; C:6-99; D:6-99; A:342-450; B:342-450; A:242-341; B:242-341CRYSTAL STRUCTURE OF HUMAN FCARI BOUND TO IGA1-FC
1OWWA:1-93SOLUTION STRUCTURE OF THE FIRST TYPE III MODULE OF HUMAN FIBRONECTIN DETERMINED BY 1H, 15N NMR SPECTROSCOPY
1P53A:185-282; B:185-282; A:368-450; B:368-450; A:283-367; B:283-367THE CRYSTAL STRUCTURE OF ICAM-1 D3-D5 FRAGMENT
1P6FA:99-191; A:4-98STRUCTURE OF THE HUMAN NATURAL CYTOTOXICITY RECEPTOR NKP46
1P7QB:1-99; A:182-270; D:97-198; D:4-96CRYSTAL STRUCTURE OF HLA-A2 BOUND TO LIR-1, A HOST AND VIRAL MHC RECEPTOR
1P9MA:202-299; A:102-201; C:196-296; C:96-195; A:2-101CRYSTAL STRUCTURE OF THE HEXAMERIC HUMAN IL-6/IL-6 ALPHA RECEPTOR/GP130 COMPLEX
1PD6A:208-301THE NMR STRUCTURE OF DOMAIN C2 OF HUMAN CARDIAC MYOSIN BINDING PROTEIN C
1PEWA:1-108; B:1-108HIGH RESOLUTION CRYSTAL STRUCTURE OF JTO2, A MUTANT OF THE NON-AMYLOIDOGENIC LAMBA6 LIGHT CHAIN, JTO
1PGRB:1-108; F:1-108; D:3-108; H:3-108; F:109-213; B:109-213; D:109-213; H:109-2132:2 COMPLEX OF G-CSF WITH ITS RECEPTOR
1PVHA:201-301; C:201-301; A:101-200; C:101-200CRYSTAL STRUCTURE OF LEUKEMIA INHIBITORY FACTOR IN COMPLEX WITH GP130
1PW3A:1-108; B:1-108CRYSTAL STRUCTURE OF JTOR68S
1PY4A:0-97; B:1-97; D:1-97; C:2-97BETA2 MICROGLOBULIN MUTANT H31Y DISPLAYS HINTS FOR AMYLOID FORMATIONS
1PYWA:82-181; B:93-190HUMAN CLASS II MHC PROTEIN HLA-DR1 BOUND TO A DESIGNED PEPTIDE RELATED TO INFLUENZA VIRUS HEMAGGLUTININ, FVKQNA(MAA)AL, IN COMPLEX WITH STAPHYLOCOCCAL ENTEROTOXIN C3 VARIANT 3B2 (SEC3-3B2)
1Q1JH:114-223; I:114-223; L:2-107; M:2-107; L:108-211; M:108-211; H:1-113; I:1-113CRYSTAL STRUCTURE ANALYSIS OF ANTI-HIV-1 FAB 447-52D IN COMPLEX WITH V3 PEPTIDE
1Q38A:1-89ANASTELLIN
1Q8MA:16-136; B:16-136; C:16-136; D:16-136CRYSTAL STRUCTURE OF THE HUMAN MYELOID CELL ACTIVATING RECEPTOR TREM-1
1Q94B:0-99; E:0-99; A:182-275; D:182-275STRUCTURES OF HLA-A*1101 IN COMPLEX WITH IMMUNODOMINANT NONAMER AND DECAMER HIV-1 EPITOPES CLEARLY REVEAL THE PRESENCE OF A MIDDLE ANCHOR RESIDUE
1QA9B:1-95; D:1-95; A:4-105; C:4-105STRUCTURE OF A HETEROPHILIC ADHESION COMPLEX BETWEEN THE HUMAN CD2 AND CD58(LFA-3) COUNTER-RECEPTORS
1QACA:1-108; B:301-408CHANGE IN DIMERIZATION MODE BY REMOVAL OF A SINGLE UNSATISFIED POLAR RESIDUE
1QEWB:0-99; A:182-270HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A 0201) COMPLEX WITH A NONAMERIC PEPTIDE FROM MELANOMA-ASSOCIATED ANTIGEN 3 (RESIDUES 271-279)
1QFWH:3-117; L:1-114; M:201-308; I:201-321TERNARY COMPLEX OF HUMAN CHORIONIC GONADOTROPIN WITH FV ANTI ALPHA SUBUNIT AND FV ANTI BETA SUBUNIT
1QG3A:1217-1320; B:1217-1319; A:1126-1216; B:1127-1216CRYSTAL STRUCTURE OF A TANDEM PAIR OF FIBRONECTIN TYPE III DOMAINS FROM THE CYTOPLASMIC TAIL OF INTEGRIN ALPHA6 BETA4
1QLRA:109-211; A:1-108; C:1-108; B:1-120; D:1-120; D:121-223; B:121-222; C:109-211CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF A HUMAN MONOCLONAL IGM COLD AGGLUTININ
1QP1A:1-107; B:1-107; C:1-107KAPPA VARIABLE LIGHT CHAIN
1QQDB:0-98; A:182-272CRYSTAL STRUCTURE OF HLA-CW4, A LIGAND FOR THE KIR2D NATURAL KILLER CELL INHIBITORY RECEPTOR
1QR1B:0-99; A:182-270; D:182-270; E:0-99POOR BINDING OF A HER-2/NEU EPITOPE (GP2) TO HLA-A2.1 IS DUE TO A LACK OF INTERACTIONS IN THE CENTER OF THE PEPTIDE
1QRKA:518-630; B:517-630; A:631-724; B:631-724; A:9-192; B:10-192HUMAN FACTOR XIII WITH STRONTIUM BOUND IN THE ION SITE
1QRNB:0-99; A:182-270; E:3-117; D:117-206; E:118-243; D:1-116CRYSTAL STRUCTURE OF HUMAN A6 TCR COMPLEXED WITH HLA-A2 BOUND TO ALTERED HTLV-1 TAX PEPTIDE P6A
1QSEB:0-99; A:182-270; E:3-117; D:117-206; E:118-243; D:1-116STRUCTURE OF HUMAN A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE V7R
1QSFB:0-99; A:182-270; E:3-117; D:117-206; E:118-243; D:1-116STRUCTURE OF A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE Y8A
1QSVA:129-229THE VEGF-BINDING DOMAIN OF FLT-1, 20 NMR STRUCTURES
1QSZA:129-229THE VEGF-BINDING DOMAIN OF FLT-1 (MINIMIZED MEAN)
1QTYT:132-225; U:132-225; X:132-225; Y:132-225VASCULAR ENDOTHELIAL GROWTH FACTOR IN COMPLEX WITH DOMAIN 2 OF THE FLT-1 RECEPTOR
1QVOB:0-99; E:0-99; A:182-275; D:182-275STRUCTURES OF HLA-A*1101 IN COMPLEX WITH IMMUNODOMINANT NONAMER AND DECAMER HIV-1 EPITOPES CLEARLY REVEAL THE PRESENCE OF A MIDDLE ANCHOR RESIDUE
1R5IA:82-181; E:82-181; B:93-190; F:93-190CRYSTAL STRUCTURE OF THE MAM-MHC COMPLEX
1REIA:1-107; B:1-107THE MOLECULAR STRUCTURE OF A DIMER COMPOSED OF THE VARIABLE PORTIONS OF THE BENCE-JONES PROTEIN REI REFINED AT 2.0 ANGSTROMS RESOLUTION
1RHFA:7-97; B:7-97; A:98-182; B:98-182CRYSTAL STRUCTURE OF HUMAN TYRO3-D1D2
1RHHA:108-210; A:1-107; C:1-107; B:114-213; D:114-213; D:4-113; B:3-113; C:108-210CRYSTAL STRUCTURE OF THE BROADLY HIV-1 NEUTRALIZING FAB X5 AT 1.90 ANGSTROM RESOLUTION
1RPQD:4-84; C:4-84; A:4-84; B:4-84; A:85-171; B:85-171; C:85-171; D:85-171HIGH AFFINITY IGE RECEPTOR (ALPHA CHAIN) COMPLEXED WITH TIGHT-BINDING E131 'ZETA' PEPTIDE FROM PHAGE DISPLAY
1RSFA:19-144NMR STRUCTURE OF MONOMERIC CAR D1 DOMAIN
1RV6X:133-224; Y:133-224CRYSTAL STRUCTURE OF PLGF IN COMPLEX WITH DOMAIN 2 OF VEGFR1
1RY7B:150-247; B:248-362CRYSTAL STRUCTURE OF THE 3 IG FORM OF FGFR3C IN COMPLEX WITH FGF1
1RZ7L:108-211; H:110-213; H:1-109; L:2-107CRYSTAL STRUCTURE OF HUMAN ANTI-HIV-1 GP120-REACTIVE ANTIBODY 48D
1RZ8A:109-211; A:1-108; C:1-108; B:114-213; D:114-213; B:1-113; D:1-113; C:109-211CRYSTAL STRUCTURE OF HUMAN ANTI-HIV-1 GP120-REACTIVE ANTIBODY 17B
1RZFH:111-214; L:3-108; H:2-110; L:109-209CRYSTAL STRUCTURE OF HUMAN ANTI-HIV-1 GP120-REACTIVE ANTIBODY E51
1RZGB:110-211; A:110-214; C:110-213; C:2-109; A:1-109; D:110-211; B:1-108; D:1-108CRYSTAL STRUCTURE OF HUMAN ANTI-HIV-1 GP120 REACTIVE ANTIBODY 412D
1RZIA:108-211; F:114-214; B:114-213; D:114-213; H:114-213; J:114-213; L:114-213; N:114-213; P:114-213; L:1-113; B:1-113; D:1-113; F:1-113; H:1-113; J:1-113; N:1-113; P:1-113; C:108-211; E:108-211; G:108-211; I:108-211; K:108-211; M:108-211; O:108-211; A:2-107; E:2-107; G:2-107; I:2-107; K:2-107; M:2-107; O:2-107; C:1-107CRYSTAL STRUCTURE OF HUMAN ANTI-HIV-1 GP120-REACTIVE ANTIBODY 47E FAB
1S78C:109-211; D:114-213; F:114-213; D:1-113; F:1-113; E:109-211; C:1-108; E:1-108INSIGHTS INTO ERBB SIGNALING FROM THE STRUCTURE OF THE ERBB2-PERTUZUMAB COMPLEX
1S8DB:1-99; A:182-270STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-3A
1S9VA:82-180; D:82-178; B:93-190; E:93-190CRYSTAL STRUCTURE OF HLA-DQ2 COMPLEXED WITH DEAMIDATED GLIADIN PEPTIDE
1S9WB:0-99; A:182-270CRYSTAL STRUCTURE ANALYSIS OF NY-ESO-1 EPITOPE, SLLMWITQC, IN COMPLEX WITH HLA-A2
1S9XB:0-99; A:182-270CRYSTAL STRUCTURE ANALYSIS OF NY-ESO-1 EPITOPE ANALOGUE, SLLMWITQA, IN COMPLEX WITH HLA-A2
1S9YB:0-99; A:182-270CRYSTAL STRUCTURE ANALYSIS OF NY-ESO-1 EPITOPE ANALOGUE, SLLMWITQS, IN COMPLEX WITH HLA-A2
1SEBA:82-181; E:82-181; B:93-192; F:93-192COMPLEX OF THE HUMAN MHC CLASS II GLYCOPROTEIN HLA-DR1 AND THE BACTERIAL SUPERANTIGEN SEB
1SJEA:82-181; B:93-190HLA-DR1 COMPLEXED WITH A 16 RESIDUE HIV CAPSID PEPTIDE BOUND IN A HAIRPIN CONFORMATION
1SJHA:82-181; B:93-190HLA-DR1 COMPLEXED WITH A 13 RESIDUE HIV CAPSID PEPTIDE
1SMOB:26-135; A:21-133CRYSTAL STRUCTURE OF HUMAN TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1 (TREM-1) AT 1.47 .
1SYSB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA, B*4403, AND PEPTIDE EEPTVIKKY
1SYVB:1-99; A:182-272HLA-B*4405 COMPLEXED TO THE DOMINANT SELF LIGAND EEFGRAYGF
1T04A:108-211; B:2-117; D:2-117; B:118-217; D:118-217; C:108-211; A:1-107; C:1-107THREE DIMENSIONAL STRUCTURE OF A HUMANIZED ANTI-IFN-GAMMA FAB IN C2 SPACE GROUP
1T0PB:1-86STRUCTURAL BASIS OF ICAM RECOGNITION BY INTEGRIN ALPAHLBETA2 REVEALED IN THE COMPLEX STRUCTURE OF BINDING DOMAINS OF ICAM-3 AND ALPHALBETA2 AT 1.65 A
1T1WB:1-99; A:182-270STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-3F6I8V
1T1XB:1-99; A:182-270STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-4L
1T1YB:1-99; A:182-270STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-5V
1T1ZB:1-99; A:182-270STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-6A
1T20B:1-99; A:182-270STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-6I
1T21B:1-99; A:182-270STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9, MONOCLINIC CRYSTAL
1T22B:1-99; A:182-270STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9, ORTHORHOMBIC CRYSTAL
1T2JA:1-113CRYSTAL STRUCTURE OF A HUMAN VH DOMAIN
1T3FA:108-211; B:2-117; B:118-217; A:1-107THREE DIMENSIONAL STRUCTURE OF A HUMANIZED ANTI-IFN-GAMMA FAB (HUZAF) IN P21 21 21 SPACE GROUP
1T5WA:82-181; D:82-181; B:93-190; E:93-190HLA-DR1 IN COMPLEX WITH A SYNTHETIC PEPTIDE (AAYSDQATPLLLSPR)
1T5XA:82-181; B:93-190HLA-DR1 IN COMPLEX WITH A SYNTHETIC PEPTIDE (AAYSDQATPLLLSPR) AND THE SUPERANTIGEN SEC3-3B2
1T7VA:184-273ZN-ALPHA-2-GLYCOPROTEIN; BACULO-ZAG PEG 200
1T7WA:184-273ZN-ALPHA-2-GLYCOPROTEIN; CHO-ZAG PEG 400
1T7XA:184-273ZN-ALPHA-2-GLYCOPROTEIN; REFOLDED CHO-ZAG PEG 400
1T7YA:184-273ZN-ALPHA-2-GLYCOPROTEIN; BACULO-ZAG PEG 200, NO GLYCEROL
1T7ZA:184-273ZN-ALPHA-2-GLYCOPROTEIN; BACULO-ZAG NO PEG, NO GLYCEROL
1T80A:184-273ZN-ALPHA-2-GLYCOPROTEIN; CHO-ZAG PEG 200
1T83A:338-443; B:338-443; A:238-337; B:238-337; C:90-171; C:5-89CRYSTAL STRUCTURE OF A HUMAN TYPE III FC GAMMA RECEPTOR IN COMPLEX WITH AN FC FRAGMENT OF IGG1 (ORTHORHOMBIC)
1T89A:338-443; B:338-443; A:238-337; B:238-337; C:90-171; C:5-89CRYSTAL STRUCTURE OF A HUMAN TYPE III FC GAMMA RECEPTOR IN COMPLEX WITH AN FC FRAGMENT OF IGG1 (HEXAGONAL)
1TENA:802-891STRUCTURE OF A FIBRONECTIN TYPE III DOMAIN FROM TENASCIN PHASED BY MAD ANALYSIS OF THE SELENOMETHIONYL PROTEIN
1TFHA:5-105; B:5-105; A:106-210; B:106-205EXTRACELLULAR DOMAIN OF HUMAN TISSUE FACTOR
1TITA:1-89TITIN, IG REPEAT 27, NMR, MINIMIZED AVERAGE STRUCTURE
1TIUA:1-89TITIN, IG REPEAT 27, NMR, 24 STRUCTURES
1TJGL:108-211; H:114-213; H:1-113; L:1-107CRYSTAL STRUCTURE OF THE BROADLY NEUTRALIZING ANTI-HIV-1 ANTIBODY 2F5 IN COMPLEX WITH A GP41 7MER EPITOPE
1TJHL:108-211; H:114-213; H:1-113; L:1-107CRYSTAL STRUCTURE OF THE BROADLY NEUTRALIZING ANTI-HIV-1 ANTIBODY 2F5 IN COMPLEX WITH A GP41 11MER EPITOPE
1TJIL:108-211; H:114-213; H:1-113; L:1-107CRYSTAL STRUCTURE OF THE BROADLY NEUTRALIZING ANTI-HIV-1 ANTIBODY 2F5 IN COMPLEX WITH A GP41 17MER EPITOPE
1TMCB:1-99THE THREE-DIMENSIONAL STRUCTURE OF A CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE MISSING THE ALPHA3 DOMAIN OF THE HEAVY CHAIN
1TNMA:1-91TERTIARY STRUCTURE OF AN IMMUNOGLOBULIN-LIKE DOMAIN FROM THE GIANT MUSCLE PROTEIN TITIN: A NEW MEMBER OF THE I SET
1TNNA:1-91TERTIARY STRUCTURE OF AN IMMUNOGLOBULIN-LIKE DOMAIN FROM THE GIANT MUSCLE PROTEIN TITIN: A NEW MEMBER OF THE I SET
1TTFA:1-94THE THREE-DIMENSIONAL STRUCTURE OF THE TENTH TYPE III MODULE OF FIBRONECTIN: AN INSIGHT INTO RGD-MEDIATED INTERACTIONS
1TTGA:1-94THE THREE-DIMENSIONAL STRUCTURE OF THE TENTH TYPE III MODULE OF FIBRONECTIN: AN INSIGHT INTO RGD-MEDIATED INTERACTIONS
1TVBB:0-99; E:0-99; A:182-270; D:182-270CRYSTAL STRUCTURE OF MELANOMA ANTIGEN GP100(209-217) BOUND TO HUMAN CLASS I MHC HLA-A2
1TVDA:1-116; B:1-116VARIABLE DOMAIN OF T CELL RECEPTOR DELTA CHAIN
1TVHB:0-99; E:0-99; A:182-270; D:182-270CRYSTAL STRUCTURE OF MODIFIED MELANOMA ANTIGEN GP100(209-T2M) BOUND TO HUMAN CLASS I MHC HLA-A2
1TZGL:109-211; L:1-108; M:1-108; I:110-228; H:110-232; H:1-109; I:1-109; M:109-211CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING HUMAN FAB 4E10 IN COMPLEX WITH A 13-RESIDUE PEPTIDE CONTAINING THE 4E10 EPITOPE ON GP41
1TZHA:109-211; B:114-213; H:114-213; B:1-113; H:1-113; L:109-211; A:1-108; L:1-108CRYSTAL STRUCTURE OF THE FAB YADS1 COMPLEXED WITH H-VEGF
1U2HA:17-112X-RAY STRUCTURE OF THE N-TERMINALLY TRUNCATED HUMAN APEP-1
1U6AL:109-211; L:1-108; H:114-212; H:2-113CRYSTAL STRUCTURE OF THE BROADLY NEUTRALIZING ANTI-HIV FAB F105
1U8HA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ALDKWAS
1U8IA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKWAN
1U8JA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKWAG
1U8KA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE LELDKWASL
1U8LA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE DLDRWAS
1U8MA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKYAS
1U8NA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKFAS
1U8OA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKHAS
1U8PA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ECDKWCS
1U8QA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELEKWAS
1U91A:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ANALOG ENDKW-[DAP]-S (CYCLIC)
1U92A:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ANALOG E-[DAP]-DKWQS (CYCLIC)
1U93A:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ANALOG EQDKW-[DAP]-S (CYCLIC)
1U95A:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDHWAS
1UADC:4-95; D:4-95CRYSTAL STRUCTURE OF THE RALA-GPPNHP-SEC5 RAL-BINDING DOMAIN COMPLEX
1UC6A:1-109SOLUTION STRUCTURE OF THE CARBOXYL TERMINAL DOMAIN OF THE CILIARY NEUROTROPHIC FACTOR RECEPTOR
1UCTA:101-195; A:6-100CRYSTAL STRUCTURE OF THE EXTRACELLULAR FRAGMENT OF FC ALPHA RECEPTOR I (CD89)
1UEMA:1-117SOLUTION STRUCTURE OF THE FIRST FIBRONECTIN TYPE III DOMAIN OF HUMAN KIAA1568 PROTEIN
1UENA:1-125SOLUTION STRUCTURE OF THE THIRD FIBRONECTIN III DOMAIN OF HUMAN KIAA0343 PROTEIN
1UEYA:1-127SOLUTION STRUCTURE OF THE FIRST FIBRONECTIN TYPE III DOMAIN OF HUMAN KIAA0343 PROTEIN
1UFUA:97-195; A:2-96CRYSTAL STRUCTURE OF LIGAND BINDING DOMAIN OF IMMUNOGLOBULIN-LIKE TRANSCRIPT 2 (ILT2; LIR-1)
1UGNA:97-198; A:2-96CRYSTAL STRUCTURE OF LIR1.02, ONE OF THE ALLELES OF LIR1
1UJ3A:109-211; B:418-517; C:606-705; C:706-810; B:301-417; A:1-108CRYSTAL STRUCTURE OF A HUMANIZED FAB FRAGMENT OF ANTI-TISSUE-FACTOR ANTIBODY IN COMPLEX WITH TISSUE FACTOR
1UJTA:1-120SOLUTION STRUCTURE OF THE SECOND FIBRONECTIN TYPE III DOMAIN OF HUMAN KIAA1568 PROTEIN
1UQSB:0-99; A:183-278THE CRYSTAL STRUCTURE OF HUMAN CD1B WITH A BOUND BACTERIAL GLYCOLIPID
1UVQA:85-183; B:93-191CRYSTAL STRUCTURE OF HLA-DQ0602 IN COMPLEX WITH A HYPOCRETIN PEPTIDE
1UXSB:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2)OF EPSTEIN-BARR VIRUS
1UXWB:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2) OF EPSTEIN-BARR VIRUS
1V05A:-3-2725DIMERIZATION OF HUMAN FILAMIN C: CRYSTAL STRUCTURE OF THE DOMAIN 24
1V5JA:1-108SOLUTION STRUCTURE OF RSGI RUH-008, FN3 DOMAIN IN HUMAN CDNA
1VCAA:90-199; B:90-199; A:1-89; B:1-89CRYSTAL STRUCTURE OF AN INTEGRIN-BINDING FRAGMENT OF VASCULAR CELL ADHESION MOLECULE-1 AT 1.8 ANGSTROMS RESOLUTION
1VDGA:97-197; B:97-197; B:2-96; A:2-96CRYSTAL STRUCTURE OF LIR1.01, ONE OF THE ALLELES OF LIR1
1VGEL:109-211; H:123-222; H:2-122; L:1-108TR1.9 FAB FRAGMENT OF A HUMAN IGG1 KAPPA AUTOANTIBODY
1VHPA:1-117VH-P8, NMR
1VSCA:90-196; B:90-196; A:1-89; B:1-89VCAM-1
1W0VB:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE SELF-PEPTIDE TIS FROM EGF-RESPONSE FACTOR 1
1W0WB:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE SELF-PEPTIDE TIS FROM EGF-RESPONSE FACTOR 1
1W0YT:6-105; T:106-210TF7A_3771 COMPLEX
1W2KT:6-105; T:106-210TF7A_4380 COMPLEX
1W72B:0-99; H:114-228; I:114-228; E:0-99; L:1-107; M:1-107; L:108-211; M:108-211; H:1-113; I:1-113; A:182-274; D:182-274CRYSTAL STRUCTURE OF HLA-A1:MAGE-A1 IN COMPLEX WITH FAB-HYB3
1WAAC:-3-89; D:-3-89; A:-2-89; B:1-89; F:-3-89; E:-3-88IG27 PROTEIN DOMAIN
1WIOA:1-98; B:1-98; A:181-291; B:181-291; A:99-180; B:99-180; A:292-363; B:292-363STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4, TETRAGONAL CRYSTAL FORM
1WIPA:1-98; B:1-98; A:181-291; B:181-291; A:99-180; B:99-180; A:292-363; B:292-363STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4, MONOCLINIC CRYSTAL FORM
1WQVT:6-105; T:106-210HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH PROPYLSULFONAMIDE-D-THR-MET-P-AMINOBENZAMIDINE
1WSST:6-105; T:106-210HUMAN FACTOR VIIA-TISSUE FACTOR IN COMPLEX WITH PEPTIDE-MIMETIC INHIBITOR THAT HAS TWO CHARGED GROUPS IN P2 AND P4
1WT5C:1-111; D:1-111; A:1-115; B:1-115THE CRYSTAL STRUCTURE OF A HUMANIZED ANTIBODY FV 528
1WTGT:6-105; T:106-210HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-BIPHENYLALANINE-GLN-P-AMINOBENZAMIDINE
1WTLA:1-108; B:1-108COMPARISON OF CRYSTAL STRUCTURES OF TWO HOMOLOGOUS PROTEINS: STRUCTURAL ORIGIN OF ALTERED DOMAIN INTERACTIONS IN IMMUNOGLOBULIN LIGHT CHAIN DIMERS
1WUNT:6-105; T:106-210HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-TRP-GLN-P-AMINOBENZAMIDINE
1WV7T:6-105; T:106-210HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5-PROPOXY-TRP-GLN-P-AMINOBENZAMIDINE
1WVZA:9-104SOLUTION STRUCTURE OF THE D2 DOMAIN OF THE FIBROBLAST GROWTH FACTOR
1WWAX:282-386; Y:278-382NGF BINDING DOMAIN OF HUMAN TRKA RECEPTOR
1WWBX:283-385LIGAND BINDING DOMAIN OF HUMAN TRKB RECEPTOR
1WWCA:300-404NT3 BINDING DOMAIN OF HUMAN TRKC RECEPTOR
1WWWX:282-382; Y:282-382NGF IN COMPLEX WITH DOMAIN 5 OF THE TRKA RECEPTOR
1X7QB:1-99; A:182-275CRYSTAL STRUCTURE OF HLA-A*1101 WITH SARS NUCLEOCAPSID PEPTIDE
1X9QA:14-124; A:149-2684M5.3 ANTI-FLUORESCEIN SINGLE CHAIN ANTIBODY FRAGMENT (SCFV)
1XH3B:1-99; A:182-272CONFORMATIONAL RESTRAINTS AND FLEXIBILITY OF 14-MERIC PEPTIDES IN COMPLEX WITH HLA-B*3501
1XIWC:1-107; D:1-122; H:1-122; A:12-102; E:12-98; B:1-74; F:2-72; G:1-107CRYSTAL STRUCTURE OF HUMAN CD3-E/D DIMER IN COMPLEX WITH A UCHT1 SINGLE-CHAIN ANTIBODY FRAGMENT
1XR8B:1-99; A:182-272CRYSTAL STRUCTURES OF HLA-B*1501 IN COMPLEX WITH PEPTIDES FROM HUMAN UBCH6 AND EPSTEIN-BARR VIRUS EBNA-3
1XR9B:1-99; A:182-272CRYSTAL STRUCTURES OF HLA-B*1501 IN COMPLEX WITH PEPTIDES FROM HUMAN UBCH6 AND EPSTEIN-BARR VIRUS EBNA-3
1XZ0B:1-98; A:183-277; C:183-277; D:1-98CRYSTAL STRUCTURE OF CD1A IN COMPLEX WITH A SYNTHETIC MYCOBACTIN LIPOPEPTIDE
1Y6KR:104-206; R:2-103CRYSTAL STRUCTURE OF HUMAN IL-10 COMPLEXED WITH THE SOLUBLE IL-10R1 CHAIN
1YA5A:1-98; B:1-98; A:99-198; B:99-197CRYSTAL STRUCTURE OF THE TITIN DOMAINS Z1Z2 IN COMPLEX WITH TELETHONIN
1YDPB:1A-99; A:182-2721.9A CRYSTAL STRUCTURE OF HLA-G
1YMMD:9-104; A:82-183; E:120-246; B:92-189; E:3-119TCR/HLA-DR2B/MBP-PEPTIDE COMPLEX
1YY9C:109-211; D:122-219; D:1-118; C:1-108STRUCTURE OF THE EXTRACELLULAR DOMAIN OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN COMPLEX WITH THE FAB FRAGMENT OF CETUXIMAB/ERBITUX/IMC-C225
1Z6JT:3-105; T:106-211CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR/PYRAZINONE INHIBITOR
1ZA6A:114-217; B:116-218; D:116-218; F:116-218; H:116-218; B:239-344; D:239-344; F:239-344; H:239-344; A:1-113; C:1-113; E:1-113; G:1-113; C:114-217; E:114-217; G:114-217; B:1-115; D:1-115; F:1-115; H:1-115THE STRUCTURE OF AN ANTITUMOR CH2-DOMAIN-DELETED HUMANIZED ANTIBODY
1ZAGA:184-273; B:184-273; C:184-273; D:184-273HUMAN ZINC-ALPHA-2-GLYCOPROTEIN
1ZGLR:0-118; V:0-118; P:-1-118; T:-1-118; A:82-181; D:82-181; G:82-181; J:82-181; T:119-247; R:119-240; P:119-244; V:119-244; K:93-189; E:93-189; B:93-189; H:93-189; M:1-115; S:1-115; Q:0-115; U:0-115CRYSTAL STRUCTURE OF 3A6 TCR BOUND TO MBP/HLA-DR2A
1ZHKB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*3501 PRESENTING 13-MER EBV ANTIGEN LPEPLPQGQLTAY
1ZHLB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*3508 PRESENTING 13-MER EBV ANTIGEN LPEPLPQGQLTAY
1ZLSL:108-210; H:114-227; H:1-113; L:2-107FAB 2G12 + MAN4
1ZLUL:108-211; H:114-227; M:114-227; H:1-113; M:1-113; K:108-211; K:2-107; L:2-107FAB 2G12 + MAN5
1ZLVK:108-212; M:114-227; H:114-227; H:1-113; M:1-113; L:108-212; K:2-107; L:2-107FAB 2G12 + MAN7
1ZLWL:108-210; H:114-228; M:114-227; H:1-113; M:1-113; K:108-211; K:2-107; L:2-107FAB 2G12 + MAN8
1ZSDB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*3501 PRESENTING AN 11-MER EBV ANTIGEN EPLPQGQLTAY
1ZT4B:0-99; C:183-281; A:183-277; D:0-99THE CRYSTAL STRUCTURE OF HUMAN CD1D WITH AND WITHOUT ALPHA-GALACTOSYLCERAMIDE
1ZXQA:86-192; A:1-85THE CRYSTAL STRUCTURE OF ICAM-2
2A2QT:6-105; T:106-210COMPLEX OF ACTIVE-SITE INHIBITED HUMAN COAGULATION FACTOR VIIA WITH HUMAN SOLUBLE TISSUE FACTOR IN THE PRESENCE OF CA2+, MG2+, NA+, AND ZN2+
2A38B:1-99; C:1-99; A:1-98; A:99-194; B:100-194; C:100-194CRYSTAL STRUCTURE OF THE N-TERMINUS OF TITIN
2A83B:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE GLUCAGON RECEPTOR (GR) PEPTIDE (RESIDUES 412-420)
2A9ML:3-147; M:2-148; H:1-148; I:1-148STRUCTURAL ANALYSIS OF A TIGHT-BINDING FLUORESCEIN-SCFV; APO FORM
2A9NL:3-149; M:2-148; H:1-148; I:1-148A MUTATION DESIGNED TO ALTER CRYSTAL PACKING PERMITS STRUCTURAL ANALYSIS OF A TIGHT-BINDING FLUORESCEIN-SCFV COMPLEX
2AAVA:-4-1956SOLUTION NMR STRUCTURE OF FILAMIN A DOMAIN 17
2ADFL:108-209; H:120-218; H:1-119; L:1-107CRYSTAL STRUCTURE AND PARATOPE DETERMINATION OF 82D6A3, AN ANTITHROMBOTIC ANTIBODY DIRECTED AGAINST THE VON WILLEBRAND FACTOR A3-DOMAIN
2AEIT:5-105; T:106-211CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR AND 2-[[6-[3-(AMINOIMINOMETHYL)PHENOXY]-3,5-DIFLURO-4-[(1-METHYL-3-PHENYLPROPYL)AMINO]-2-PYRIDINYL]OXY]-BENZOIC ACID
2AERT:5-105; T:106-206CRYSTAL STRUCTURE OF BENZAMIDINE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX.
2AEWB:132-233; A:132-233; A:29-131; B:31-131A MODEL FOR GROWTH HORMONE RECEPTOR ACTIVATION BASED ON SUBUNIT ROTATION WITHIN A RECEPTOR DIMER
2AGJL:110-212; L:1-109; H:2-120; H:121-221CRYSTAL STRUCTURE OF A GLYCOSYLATED FAB FROM AN IGM CRYOGLOBULIN WITH PROPERTIES OF A NATURAL PROTEOLYTIC ANTIBODY
2AJ3A:110-211; B:114-212; D:114-212; F:114-212; B:2-113; D:2-113; F:2-113; C:110-211; E:110-211; A:2-108; C:2-108; E:2-108CRYSTAL STRUCTURE OF A CROSS-REACTIVE HIV-1 NEUTRALIZING CD4-BINDING SITE ANTIBODY FAB M18
2AK4B:1-99; U:3-118; E:3-118; J:3-118; P:3-118; G:1-99; L:1-99; R:1-99; E:119-244; J:119-244; P:119-244; U:119-244; D:1-116; I:1-116; N:1-116; T:1-116; A:182-272; F:182-272; K:182-272; Q:182-272CRYSTAL STRUCTURE OF SB27 TCR IN COMPLEX WITH HLA-B*3508-13MER PEPTIDE
2ARWA:1-103THE SOLUTION STRUCTURE OF THE MEMBRANE PROXIMAL CYTOKINE RECEPTOR DOMAIN OF THE HUMAN INTERLEUKIN-6 RECEPTOR
2AV1B:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF HTLV-1 TAX PEPTIDE BOUND TO HUMAN CLASS I MHC HLA-A2 WITH THE E63Q AND K66A MUTATIONS IN THE HEAVY CHAIN.
2AV7B:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF HTLV-1 TAX PEPTIDE BOUND TO HUMAN CLASS I MHC HLA-A2 WITH THE K66A MUTATION IN THE HEAVY CHAIN.
2AW2X:34-140; A:34-143CRYSTAL STRUCTURE OF THE HUMAN BTLA-HVEM COMPLEX
2AXFB:1-99; A:182-272THE IMMUNOGENICITY OF A VIRAL CYTOTOXIC T CELL EPITOPE IS CONTROLLED BY ITS MHC-BOUND CONFORMATION
2AXGB:1-99; A:182-272THE IMMUNOGENICITY OF A VIRAL CYTOTOXIC T CELL EPITOPE IS CONTROLLED BY ITS MHC-BOUND CONFORMATION
2AXHA:3-115; B:3-115; A:116-244; B:116-244CRYSTAL STRUCTURES OF T CELL RECEPTOR BETA CHAINS RELATED TO RHEUMATOID ARTHRITIS
2AXJA:3-115; B:3-115; A:116-244; B:116-244CRYSTAL STRUCTURES OF T CELL RECEPTOR BETA CHAINS RELATED TO RHEUMATOID ARTHRITIS
2B0SH:114-225; L:2-107; H:1-113; L:108-211CRYSTAL STRUCTURE ANALYSIS OF ANTI-HIV-1 V3 FAB 2219 IN COMPLEX WITH MN PEPTIDE
2B1AH:114-225; L:2-107; H:1-113; L:108-211CRYSTAL STRUCTURE ANALYSIS OF ANTI-HIV-1 V3 FAB 2219 IN COMPLEX WITH UG1033 PEPTIDE
2B1HH:114-225; L:2-107; H:1-113; L:108-211CRYSTAL STRUCTURE ANALYSIS OF ANTI-HIV-1 V3 FAB 2219 IN COMPLEX WITH UG29 PEPTIDE
2B7DT:6-205FACTOR VIIA INHIBITORS: CHEMICAL OPTIMIZATION, PRECLINICAL PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY IN A BABOON THROMBOSIS MODEL
2B8OT:6-105; T:106-210CRYSTAL STRUCTURE OF GLU-GLY-ARG-CHLOROMETHYL KETONE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX
2BC4D:93-199; B:93-193; A:92-200; C:92-206CRYSTAL STRUCTURE OF HLA-DM
2BCKB:0-99; E:0-99; A:182-272; D:182-272CRYSTAL STRUCTURE OF HLA-A*2402 COMPLEXED WITH A TELOMERASE PEPTIDE
2BK8A:0-96M1 DOMAIN FROM TITIN
2BNQB:0-99; D:2-114; E:2-113; D:115-204; E:114-239; A:182-270STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL VACCINES
2BNRB:0-99; A:182-270; D:2-114; E:2-113; D:115-204; E:114-239STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL VACCINES
2BNUA:2-114; B:2-113; A:115-204; B:114-239STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL VACCINES
2BP3A:-1-1955; B:1865-1955CRYSTAL STRUCTURE OF FILAMIN A DOMAIN 17 AND GPIB ALPHA CYTOPLASMIC DOMAIN COMPLEX
2BRQA:2236-2329; B:2236-2329CRYSTAL STRUCTURE OF THE FILAMIN A REPEAT 21 COMPLEXED WITH THE INTEGRIN BETA7 CYTOPLASMIC TAIL PEPTIDE
2BSRB:0-99; A:182-276CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
2BSSB:0-99; A:182-276CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
2BSTB:0-99; A:182-276CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
2BVOB:1-99; A:182-272STRUCTURES OF THREE HIV-1 HLA-B5703-PEPTIDE COMPLEXES AND IDENTIFICATION OF RELATED HLAS POTENTIALLY ASSOCIATED WITH LONG-TERM NON-PROGRESSION
2BVPB:1-99; A:182-272STRUCTURES OF THREE HIV-1 HLA-B5703-PEPTIDE COMPLEXES AND IDENTIFICATION OF RELATED HLAS POTENTIALLY ASSOCIATED WITH LONG-TERM NON-PROGRESSION
2BVQB:1-99; A:182-272STRUCTURES OF THREE HIV-1 HLA-B5703-PEPTIDE COMPLEXES AND IDENTIFICATION OF RELATED HLAS POTENTIALLY ASSOCIATED WITH LONG-TERM NON-PROGRESSION
2C5DC:131-218; D:131-218; C:27-130; D:27-130STRUCTURE OF A MINIMAL GAS6-AXL COMPLEX
2C7UB:0-99; A:182-270; D:182-270; E:0-99CONFLICTING SELECTIVE FORCES AFFECT CD8 T-CELL RECEPTOR CONTACT SITES IN AN HLA-A2 IMMUNODOMINANT HIV EPITOPE.
2CD0A:1-108; B:1-108STRUCTURE OF HUMAN LAMBDA-6 LIGHT CHAIN DIMER WIL
2CDEA:2-114; C:2-114; E:2-114; B:2-116; D:2-116; F:2-116; B:117-242; D:117-242; F:117-242STRUCTURE AND BINDING KINETICS OF THREE DIFFERENT HUMAN CD1D-ALPHA-GALACTOSYLCERAMIDE SPECIFIC T CELL RECEPTORS - INKT-TCR
2CDFA:3-114; B:2-116; B:117-242STRUCTURE AND BINDING KINETICS OF THREE DIFFERENT HUMAN CD1D-ALPHA-GALACTOSYLCERAMIDE-SPECIFIC T CELL RECEPTORS (TCR 5E)
2CDGA:10-114; B:3-117; B:118-243STRUCTURE AND BINDING KINETICS OF THREE DIFFERENT HUMAN CD1D-ALPHA-GALACTOSYLCERAMIDE-SPECIFIC T CELL RECEPTORS (TCR 5B)
2CIKB:1-99; A:182-272INSIGHTS INTO CROSSREACTIVITY IN HUMAN ALLORECOGNITION: THE STRUCTURE OF HLA-B35011 PRESENTING AN EPITOPE DERIVED FROM CYTOCHROME P450.
2CK2B:1-96; A:1-96STRUCTURE OF CORE-SWAPPED MUTANT OF FIBRONECTIN
2CLRB:0-99; E:0-99; A:182-275; D:182-275THREE DIMENSIONAL STRUCTURE OF A PEPTIDE EXTENDING OUT ONE END OF A CLASS I MHC BINDING SITE
2CMRL:108-207; H:114-211; H:3-113; L:1-107CRYSTAL STRUCTURE OF THE HIV-1 NEUTRALIZING ANTIBODY D5 FAB BOUND TO THE GP41 INNER-CORE MIMETIC 5-HELIX
2CQVA:1-114SOLUTION STRUCTURE OF THE EIGHTH IG-LIKE DOMAIN OF HUMAN MYOSIN LIGHT CHAIN KINASE
2CUMA:1-105THE SOLUTION STRUCTURE OF THE 33RD FIBRONECTIN TYPE III DOMAIN OF HUMAN TENASCIN-X
2D31B:1-99; A:182-272; D:182-272; E:1-99CRYSTAL STRUCTURE OF DISULFIDE-LINKED HLA-G DIMER
2D3VA:96-195; A:3-95CRYSTAL STRUCTURE OF LEUKOCYTE IG-LIKE RECEPTOR A5 (LILRA5/LIR9/ILT11)
2D4DA:0-95THE CRYSTAL STRUCTURE OF HUMAN BETA2-MICROGLOBULIN, L39W W60F W95F MUTANT
2D4FA:0-97THE CRYSTAL STRUCTURE OF HUMAN BETA2-MICROGLOBULIN
2D7TL:1-110; H:1-116CRYSTAL STRUCTURE OF HUMAN ANTI POLYHYDROXYBUTYRATE ANTIBODY FV
2D9QB:97-204; B:205-308CRYSTAL STRUCTURE OF THE HUMAN GCSF-RECEPTOR SIGNALING COMPLEX
2DBJA:16-124SOLUTION STRUCTURES OF THE FN3 DOMAIN OF HUMAN PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER PRECURSOR
2DD8H:114-216; L:2-108; H:2-113; L:109-213CRYSTAL STRUCTURE OF SARS-COV SPIKE RECEPTOR-BINDING DOMAIN COMPLEXED WITH NEUTRALIZING ANTIBODY
2DF3A:24-144THE STRUCTURE OF SIGLEC-7 IN COMPLEX WITH ALPHA(2,3)/ALPHA(2,6) DISIALYL LACTOTETRAOSYL 2-(TRIMETHYLSILYL)ETHYL
2DICA:7-100SOLUTION STRUCTURE OF THE 12TH FILAMIN DOMAIN FROM HUMAN FILAMIN-B
2DJ4A:7-103SOLUTION STRUCTURE OF THE 13TH FILAMIN DOMAIN FROM HUMAN FILAMIN-B
2DJSA:13-100SOLUTION STRUCTURES OF THE FN3 DOMAIN OF HUMAN EPHRIN TYPE-B RECEPTOR 1
2DKSA:1-130SOLUTION STRUCTURE OF THE FIRST IG-LIKE DOMAIN OF HUMAN CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 8
2DL2A:103-200; A:5-102KILLER IMMUNOGLOBULIN RECEPTOR 2DL2
2DLIA:103-200; A:5-102KILLER IMMUNOGLOBULIN RECEPTOR 2DL2,TRIGONAL FORM
2DM2A:1-110SOLUTION STRUCTURE OF THE FIRST IG DOMAIN OF HUMAN PALLADIN
2DTQ  [entry was replaced by entry 3AVE without any CATH domain information]
2DTSA:338-443; B:338-443; A:238-337; B:238-337CRYSTAL STRUCTURE OF THE DEFUCOSYLATED FC FRAGMENT FROM HUMAN IMMUNOGLOBULIN G1
2DYPB:0-99; A:182-272; D:96-195; D:3-95CRYSTAL STRUCTURE OF LILRB2(LIR2/ILT4/CD85D) COMPLEXED WITH HLA-G
2E7HA:13-101SOLUTION STRUCTURE OF THE SECOND FN3 DOMAIN FROM HUMAN EPHRIN TYPE-B RECEPTOR 4
2E9WA:208-310; B:208-310; A:311-412; B:311-412; A:117-207; B:117-207; B:413-507; A:413-507; A:33-116; B:33-116CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF KIT IN COMPLEX WITH STEM CELL FACTOR (SCF)
2EC8A:208-311; A:312-411; A:11-116; A:117-207; A:412-508CRYSTAL STRUCTURE OF THE EXCTRACELLULAR DOMAIN OF THE RECEPTOR TYROSINE KINASE, KIT
2EC9U:91-210; T:6-80CRYSTAL STRUCTURE ANALYSIS OF HUMAN FACTOR VIIA , SOULUBLE TISSUE FACTOR COMPLEXED WITH BCX-3607
2EEDA:1-101SOLUTION STRUCTURE OF THE 24TH FILAMIN DOMAIN FROM HUMAN FILAMIN-B
2EIZA:1-107; B:1-113CRYSTAL STRUCTURE OF HUMANIZED HYHEL-10 FV MUTANT(HW47Y)-HEN LYSOZYME COMPLEX
2EKSA:1-107; B:1-113CRYSTAL STRUCTURE OF HUMANIZED HYHEL-10 FV-HEN LYSOZYME COMPLEX
2ESVB:0-99; A:182-272; D:4-115; E:3-118; E:119-247STRUCTURE OF THE HLA-E-VMAPRTLIL/KK50.4 TCR COMPLEX
2EYRA:1-116; B:3-118; B:119-244A STRUCTURAL BASIS FOR SELECTION AND CROSS-SPECIES REACTIVITY OF THE SEMI-INVARIANT NKT CELL RECEPTOR IN CD1D/GLYCOLIPID RECOGNITION
2EYSA:1-116; B:3-118; B:119-244A STRUCTURAL BASIS FOR SELECTION AND CROSS-SPECIES REACTIVITY OF THE SEMI-INVARIANT NKT CELL RECEPTOR IN CD1D/GLYCOLIPID RECOGNITION
2EYTA:1-116; C:1-116; B:3-118; D:3-118; B:119-244; D:119-244A STRUCTURAL BASIS FOR SELECTION AND CROSS-SPECIES REACTIVITY OF THE SEMI-INVARIANT NKT CELL RECEPTOR IN CD1D/GLYCOLIPID RECOGNITION
2F53B:0-99; A:182-270; D:-1-113; E:-1-112; E:113-238DIRECTED EVOLUTION OF HUMAN T-CELL RECEPTOR CDR2 RESIDUES BY PHAGE DISPLAY DRAMATICALLY ENHANCES AFFINITY FOR COGNATE PEPTIDE-MHC WITHOUT APPARENT CROSS-REACTIVITY
2F54B:0-99; A:182-270; F:182-270; D:1-113; K:0-113; E:1-112; L:1-112; E:113-238; L:113-238; G:0-99DIRECTED EVOLUTION OF HUMAN T CELL RECEPTOR CDR2 RESIDUES BY PHAGE DISPLAY DRAMATICALLY ENHANCES AFFINITY FOR COGNATE PEPTIDE-MHC WITHOUT INCREASING APPARENT CROSS-REACTIVITY
2F5AL:108-211; H:133-231; H:1-132; L:1-107CRYSTAL STRUCTURE OF FAB' FROM THE HIV-1 NEUTRALIZING ANTIBODY 2F5
2F5BL:108-211; H:133-232; H:1-132; L:1-107CRYSTAL STRUCTURE OF FAB' FROM THE HIV-1 NEUTRALIZING ANTIBODY 2F5 IN COMPLEX WITH ITS GP41 EPITOPE
2F8OA:4-97; B:4-97A NATIVE TO AMYLOIDOGENIC TRANSITION REGULATED BY A BACKBONE TRIGGER
2F8VB:1-98; A:2-98; D:2-98; C:4-98; B:99-197; A:99-195; C:99-194; D:99-194STRUCTURE OF FULL LENGTH TELETHONIN IN COMPLEX WITH THE N-TERMINUS OF TITIN
2F9BT:6-205DISCOVERY OF NOVEL HETEROCYCLIC FACTOR VIIA INHIBITORS
2FB4H:119-218; L:1-109; L:110-210; H:1-118DIR PRIMAERSTRUKTUR DES KRISTALLISIERBAREN MONOKLONALEN IMMUNOGLOBULINS IGG1 KOL. II. AMINOSAEURESEQUENZ DER L-KETTE, LAMBDA-TYP, SUBGRUPPE I (GERMAN)
2FCBA:92-178; A:6-91HUMAN FC GAMMA RECEPTOR IIB ECTODOMAIN (CD32)
2FD6L:108-210; H:115-208; H:1-114; L:1-107STRUCTURE OF HUMAN UROKINASE PLASMINOGEN ACTIVATOR IN COMPLEX WITH UROKINASE RECEPTOR AND AN ANTI-UPAR ANTIBODY AT 1.9 A
2FDBP:2151-2250; R:3151-3250; P:2251-2357; R:3251-3357CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR (FGF)8B IN COMPLEX WITH FGF RECEPTOR (FGFR) 2C
2FIRT:6-105; T:106-210CRYSTAL STRUCTURE OF DFPR-VIIA/STF
2FJFA:109-211; B:121-223; D:121-223; F:121-223; H:121-223; I:121-223; K:121-223; N:121-223; P:121-223; R:121-223; T:121-223; V:121-223; X:121-223; B:1-120; D:1-120; F:1-120; H:1-120; I:1-120; K:1-120; N:1-120; P:1-120; R:1-120; T:1-120; V:1-120; X:1-120; C:109-211; E:109-211; G:109-211; J:109-211; L:109-211; M:109-211; O:109-211; Q:109-211; S:109-211; U:109-211; W:109-211; A:1-108; C:1-108; E:1-108; G:1-108; J:1-108; L:1-108; M:1-108; O:1-108; Q:1-108; S:1-108; U:1-108; W:1-108STRUCTURE OF THE G6 FAB, A PHAGE DERIVED VEGF BINDING FAB
2FJGA:109-211; B:121-223; H:121-223; B:1-120; H:1-120; L:109-211; A:1-108; L:1-108STRUCTURE OF THE G6 FAB, A PHAGE DERIVED FAB FRAGMENT, IN COMPLEX WITH VEGF
2FJHL:109-214; B:122-224; H:122-224; B:1-121; H:1-121; A:109-211; A:1-108; L:1-108STRUCTURE OF THE B20-4 FAB, A PHAGE DERIVED FAB FRAGMENT, IN COMPLEX WITH VEGF
2FL5B:114-225; D:114-225; F:114-225; H:114-225; A:1-107; C:1-107; E:1-107; L:1-107; A:108-212; C:108-212; E:108-212; L:108-212; B:1-113; D:1-113; F:1-113; H:1-113COFACTOR-CONTAINING ANTIBODIES: CRYSTAL STRUCTURE OF THE ORIGINAL YELLOW ANTIBODY
2FLBT:6-205DISCOVERY OF A NOVEL HYDROXY PYRAZOLE BASED FACTOR IXA INHIBITOR
2FLRT:6-205NOVEL 5-AZAINDOLE FACTOR VIIA INHIBITORS
2FNBA:1-95NMR STRUCTURE OF THE FIBRONECTIN ED-B DOMAIN, NMR, 20 STRUCTURES
2FSEA:82-181; C:82-180; B:93-190; D:93-189CRYSTALLOGRAPHIC STRUCTURE OF A RHEUMATOID ARTHRITIS MHC SUSCEPTIBILITY ALLELE, HLA-DR1 (DRB1*0101), COMPLEXED WITH THE IMMUNODOMINANT DETERMINANT OF HUMAN TYPE II COLLAGEN
2FX7L:109-211; L:1-108; H:110-228; H:1-109CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING HUMAN FAB 4E10 IN COMPLEX WITH A 16-RESIDUE PEPTIDE ENCOMPASSING THE 4E10 EPITOPE ON GP41
2FX8L:109-211; L:1-108; M:1-108; N:1-108; O:1-108; H:110-227; I:110-227; J:110-227; K:110-227; H:1-109; I:1-109; J:1-109; K:1-109; M:109-211; N:109-211; O:109-211CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING HUMAN FAB 4E10 IN COMPLEX WITH AN AIB-INDUCED PEPTIDE ENCOMPASSING THE 4E10 EPITOPE ON GP41
2FX9L:109-211; L:1-108; M:1-108; H:110-227; I:110-227; H:1-109; I:1-109; M:109-211CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING HUMAN FAB 4E10 IN COMPLEX WITH A THIOETHER-LINKED PEPTIDE ENCOMPASSING THE 4E10 EPITOPE ON GP41
2FYYB:1-99; A:182-272THE ROLE OF T CELL RECEPTOR ALPHA GENES IN DIRECTING HUMAN MHC RESTRICTION
2FZ3B:1-99; A:182-272THE ROLE OF T CELL RECEPTOR ALPHA GENES IN DIRECTING HUMAN MHC RESTRICTION
2G5RA:24-144CRYSTAL STRUCTURE OF SIGLEC-7 IN COMPLEX WITH METHYL-9-(AMINOOXALYL-AMINO)-9-DEOXYNEU5AC (OXAMIDO-NEU5AC)
2G75A:114-214; C:114-214; B:2-108; D:2-108; A:2-113; C:2-113; B:109-211; D:109-211CRYSTAL STRUCTURE OF ANTI-SARS M396 ANTIBODY
2G9HA:82-181; B:93-190CRYSTAL STRUCTURE OF STAPHYLOCOCCAL ENTEROTOXIN I (SEI) IN COMPLEX WITH A HUMAN MHC CLASS II MOLECULE
2GI7A:89-183; B:89-183; B:0-88; A:2-88CRYSTAL STRUCTURE OF HUMAN PLATELET GLYCOPROTEIN VI (GPVI)
2GITB:0-99; E:0-99; A:182-270; D:182-270HUMAN CLASS I MHC HLA-A2 IN COMPLEX WITH THE MODIFIED HTLV-1 TAX (Y5K-4-[3-INDOLYL]-BUTYRIC ACID) PEPTIDE
2GJ6B:0-99; A:182-270; E:3-117; D:117-206; E:118-243; D:1-116THE COMPLEX BETWEEN TCR A6 AND HUMAN CLASS I MHC HLA-A2 WITH THE MODIFIED HTLV-1 TAX (Y5K-4-[3-INDOLYL]-BUTYRIC ACID) PEPTIDE
2GK2A:1-107; B:1-107CRYSTAL STRUCTURE OF THE N TERMINAL DOMAIN OF HUMAN CEACAM1
2GT9B:0-99; E:0-99; A:182-270; D:182-270HUMAN CLASS I MHC HLA-A2 IN COMPLEX WITH THE DECAMERIC MELAN-A/MART-1(26-35) PEPTIDE
2GTWB:0-99; E:0-99; A:182-270; D:182-270HUMAN CLASS I MHC HLA-A2 IN COMPLEX WITH THE NONAMERIC MELAN-A/MART-1(27-35) PEPTIDE HAVING A27L SUBSTITUTION
2GTZB:0-99; E:0-99; A:182-270; D:182-270HUMAN CLASS I MHC HLA-A2 IN COMPLEX WITH THE NONAMERIC MELAN-A/MART-1(27-35) PEPTIDE HAVING A28L SUBSTITUTION
2GUOB:0-99; A:182-270; D:182-270; E:0-99HUMAN CLASS I MHC HLA-A2 IN COMPLEX WITH THE NATIVE NONAMERIC MELAN-A/MART-1(27-35) PEPTIDE
2GW5A:97-198; A:3-96CRYSTAL STRUCTURE OF LIR-2 (ILT4) AT 1.8 : DIFFERENCES FROM LIR-1 (ILT2) IN REGIONS IMPLICATED IN THE BINDING OF THE CYTOMEGALOVIRUS CLASS I MHC HOMOLOG UL18
2GY5A:23-121; A:347-445; A:122-211TIE2 LIGAND-BINDING DOMAIN CRYSTAL STRUCTURE
2GY7B:23-121; B:347-445; B:122-211ANGIOPOIETIN-2/TIE2 COMPLEX CRYSTAL STRUCTURE
2GYSA:109-215; B:109-215; B:320-418; A:320-418; A:1-95; B:1-95; A:218-308; B:218-3082.7 A STRUCTURE OF THE EXTRACELLULAR DOMAINS OF THE HUMAN BETA COMMON RECEPTOR INVOLVED IN IL-3, IL-5, AND GM-CSF SIGNALLING
2H26B:1-99; A:183-278HUMAN CD1B IN COMPLEX WITH ENDOGENOUS PHOSPHATIDYLCHOLINE AND SPACER
2H32H:1-119; H:120-221; A:1-111CRYSTAL STRUCTURE OF THE PRE-B CELL RECEPTOR
2H3NA:2-100; C:1-99CRYSTAL STRUCTURE OF A SURROGATE LIGHT CHAIN (LAMBDA5 AND VPREB) HOMODIMER
2H6PB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*3501 PRESENTING THE HUMAN CYTOCHROME P450 DERIVED PEPTIDE, KPIVVLHGY
2H9GA:109-211; B:114-213; H:114-213; B:1-113; H:1-113; L:109-211; A:1-108; L:1-108CRYSTAL STRUCTURE OF PHAGE DERIVED FAB BDF1 WITH HUMAN DEATH RECEPTOR 5 (DR5)
2HFFA:108-213; B:114-214; H:114-213; H:1-113; B:1-113; L:108-210; A:2-107; L:1-107CRYSTAL STRUCTURE OF CB2 FAB
2HFGL:108-212; H:114-214; H:1-113; L:1-107CRYSTAL STRUCTURE OF HBR3 BOUND TO CB3S-FAB
2HFTA:1-107; A:108-211THE CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF HUMAN TISSUE FACTOR AT 1.7 ANGSTROMS RESOLUTION
2HJKB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B5703 AND HIV-1 PEPTIDE
2HJLB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B5703 AND HIV-1 PEPTIDE
2HLAB:1-99; A:182-270SPECIFICITY POCKETS FOR THE SIDE CHAINS OF PEPTIDE ANTIGENS IN HLA-AW68
2HN7B:1-99; A:182-274HLA-A*1101 IN COMPLEX WITH HBV PEPTIDE HOMOLOGUE
2HP4A:1-114; B:1-114COMPUTATIONAL DESIGN AND CRYSTAL STRUCTURE OF AN ENHANCED AFFINITY MUTANT HUMAN CD8-ALPHA-ALPHA CO-RECEPTOR
2HRLA:25-144SIGLEC-7 IN COMPLEX WITH GT1B
2HYMA:1-106; A:107-212NMR BASED DOCKING MODEL OF THE COMPLEX BETWEEN THE HUMAN TYPE I INTERFERON RECEPTOR AND HUMAN INTERFERON ALPHA-2
2IALB:2-111; D:2-111; A:1-108; C:1-108; B:112-237; D:112-237STRUCTURAL BASIS FOR RECOGNITION OF MUTANT SELF BY A TUMOR-SPECIFIC, MHC CLASS II-RESTRICTED TCR
2IAMD:2-111; A:82-181; C:1-108; D:112-237; B:93-190STRUCTURAL BASIS FOR RECOGNITION OF MUTANT SELF BY A TUMOR-SPECIFIC, MHC CLASS II-RESTRICTED TCR
2IANE:3-111; O:3-111; T:3-111; J:2-111; A:82-181; F:82-181; K:82-181; P:82-181; D:1-108; I:1-108; N:1-108; S:1-108; E:112-237; J:112-237; O:112-237; T:112-237; L:93-190; Q:93-190; B:93-190; G:93-190STRUCTURAL BASIS FOR RECOGNITION OF MUTANT SELF BY A TUMOR-SPECIFIC, MHC CLASS II-RESTRICTED TCR
2ICWL:3-113; J:1-113; A:82-181; D:82-181; E:93-190; B:93-190; K:2-110; I:1-110CRYSTAL STRUCTURE OF A COMPLETE TERNARY COMPLEX BETWEEN TCR, SUPERANTIGEN, AND PEPTIDE-MHC CLASS II MOLECULE
2IFGA:283-381; B:283-381; A:193-282; B:193-282STRUCTURE OF THE EXTRACELLULAR SEGMENT OF HUMAN TRKA IN COMPLEX WITH NERVE GROWTH FACTOR
2IG2H:119-221; L:1-109; L:110-210; H:1-118DIR PRIMAERSTRUKTUR DES KRISTALLISIERBAREN MONOKLONALEN IMMUNOGLOBULINS IGG1 KOL. II. AMINOSAEURESEQUENZ DER L-KETTE, LAMBDA-TYP, SUBGRUPPE I (GERMAN)
2ILLA:98-195; A:1-97ANOMALOUS SUBSTRUCTURE OF TITIN-A168169
2IPKA:82-181; B:93-190CRYSTAL STRUCTURE OF THE MHC CLASS II MOLECULE HLA-DR1 IN COMPLEX WITH THE FLUOROGENIC PEPTIDE, ACPKXVKQNTLKLAT (X=3-[5-(DIMETHYLAMINO)-1,3-DIOXO-1,3-DIHYDRO-2H-ISOINDOL-2-YL]-L-ALANINE) AND THE SUPERANTIGEN, SEC3 VARIANT 3B2
2IWGA:338-443; D:338-443; A:238-337; D:238-337COMPLEX BETWEEN THE PRYSPRY DOMAIN OF TRIM21 AND IGG FC
2J6EA:338-443; B:338-443; L:1-108; M:1-108; H:1-113; I:1-113; L:109-208; M:109-208; A:238-337; B:238-337; I:114-214; H:114-214CRYSTAL STRUCTURE OF AN AUTOIMMUNE COMPLEX BETWEEN A HUMAN IGM RHEUMATOID FACTOR AND IGG1 FC REVEALS A NOVEL FC EPITOPE AND EVIDENCE FOR AFFINITY MATURATION
2J8HA:98-195; A:1-97STRUCTURE OF THE IMMUNOGLOBULIN TANDEM REPEAT A168-A169 OF TITIN
2J8OA:98-195; B:98-195; A:0-97; B:1-97STRUCTURE OF THE IMMUNOGLOBULIN TANDEM REPEAT OF TITIN A168-A169
2JB5H:121-222; L:3-112; H:3-120; L:113-214FAB FRAGMENT IN COMPLEX WITH SMALL MOLECULE HAPTEN, CRYSTAL FORM-1
2JB6B:121-221; H:121-221; L:4-112; A:3-112; H:3-120; B:3-120; A:113-214; L:113-214FAB FRAGMENT IN COMPLEX WITH SMALL MOLECULE HAPTEN, CRYSTAL FORM-2
2JCCB:0-99; A:182-270; H:182-270; F:3-117; M:3-117; I:0-99; F:118-245; M:118-245; E:1-116; L:1-116AH3 RECOGNITION OF MUTANT HLA-A2 W167A
2JLLA:593-689CRYSTAL STRUCTURE OF NCAM2 IGIV-FN3II
2K7PA:1866-1956FILAMIN A IG-LIKE DOMAINS 16-17
2K7QA:-3-1968,A:2047-2141FILAMIN A IG-LIKE DOMAINS 18-19
2KBGA:1-102SOLUTION STRUCTURE OF THE SECOND FIBRONECTIN TYPE-III MODULE OF NCAM2
2KH2B:130-248SOLUTION STRUCTURE OF A SCFV-IL-1B COMPLEX
2KZ1B:11-106; B:107-206INTER-MOLECULAR INTERACTIONS IN A 44 KDA INTERFERON-RECEPTOR COMPLEX DETECTED BY ASYMMETRIC BACK-PROTONATION AND 2D NOESY
2LVEA:1-107RECOMBINANT LEN
2MCG1:2-111; 2:2-111; 1:112-216; 2:112-212THREE-DIMENSIONAL STRUCTURE OF A LIGHT CHAIN DIMER CRYSTALLIZED IN WATER. CONFORMATIONAL FLEXIBILITY OF A MOLECULE IN TWO CRYSTAL FORMS
2NMSA:18-129THE CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF THE INHIBITOR RECEPTOR EXPRESSED ON MYELOID CELLS IREM-1
2NNAA:82-180; B:93-190STRUCTURE OF THE MHC CLASS II MOLECULE HLA-DQ8 BOUND WITH A DEAMIDATED GLUTEN PEPTIDE
2NQCA:2482-2578CRYSTAL STRUCTURE OF IG-LIKE DOMAIN 23 FROM HUMAN FILAMIN C
2NTSP:3-118; P:119-245CRYSTAL STRUCTURE OF SEK-HVB5.1
2NW2A:1-116; B:1-118; B:119-244CRYSTAL STRUCTURE OF ELS4 TCR AT 1.4A
2NW3B:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*3508 PRESENTING EBV PEPTIDE EPLPQGQLTAY AT 1.7A
2NX5B:1-99; D:1-116; I:1-116; N:1-116; T:1-116; E:1-118; J:1-118; P:1-118; U:1-118; E:119-244; J:119-244; P:119-244; G:1-99; U:119-244; L:1-99; R:1-99; A:182-272; F:182-272; K:182-272; Q:182-272CRYSTAL STRUCTURE OF ELS4 TCR BOUND TO HLA-B*3501 PRESENTING EBV PEPTIDE EPLPQGQLTAY AT 1.7A
2NZIA:95-194; B:95-194; A:-1-93; B:-1-93; A:196-289; B:196-289CRYSTAL STRUCTURE OF DOMAINS A168-A170 FROM TITIN
2OCFD:2-94HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH ESTRADIOL AND THE E2#23 FN3 MONOBODY
2OJEA:82-181; E:82-181; B:93-190; F:93-190MYCOPLASMA ARTHRITIDIS-DERIVED MITOGEN COMPLEXED WITH CLASS II MHC MOLECULE HLA-DR1/HA COMPLEX IN THE PRESENCE OF EDTA
2OLDA:2-112; B:2-112; A:113-213; B:113-213BENCE JONES KWR PROTEIN- IMMUNOGLOBULIN LIGHT CHAIN DIMER, P3(2)21 CRYSTAL FORM
2OM5A:101-205; A:4-100; A:295-384; A:206-294N-TERMINAL FRAGMENT OF HUMAN TAX1
2OMBA:2-112; B:2-112; C:2-112; D:2-112; D:113-214; A:113-213; B:113-213; C:113-213BENCE JONES KWR PROTEIN- IMMUNOGLOBULIN LIGHT CHAIN DIMER, P3(1)21 CRYSTAL FORM
2OMNA:2-112; B:2-112; A:113-213; B:113-213BENCE JONES KWR PROTEIN- IMMUNOGLOBULIN LIGHT CHAIN DIMER, P4(3)2(1)2 CRYSTAL FORM
2OQJA:108-212; B:114-228; E:114-228; H:114-228; K:114-228; B:1-113; E:1-113; H:1-113; K:1-113; D:108-212; G:108-212; J:108-212; A:2-107; D:2-107; G:2-107; J:2-107CRYSTAL STRUCTURE ANALYSIS OF FAB 2G12 IN COMPLEX WITH PEPTIDE 2G12.1
2OZ4L:109-211; H:115-214; H:1-114; L:1-108STRUCTURAL PLASTICITY IN IGSF DOMAIN 4 OF ICAM-1 MEDIATES CELL SURFACE DIMERIZATION
2P5EB:0-99; D:0-114; E:1-112; E:113-238; A:182-270CRYSTAL STRUCTURES OF HIGH AFFINITY HUMAN T-CELL RECEPTORS BOUND TO PMHC REVEAL NATIVE DIAGONAL BINDING GEOMETRY
2P5WB:0-99; A:182-270; D:1-114; E:0-112; E:113-238CRYSTAL STRUCTURES OF HIGH AFFINITY HUMAN T-CELL RECEPTORS BOUND TO PMHC REVEAL NATIVE DIAGONAL BINDING GEOMETRY
2P8LA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELLELDKWASLWN
2P8MA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELLELDKWASLWN IN NEW CRYSTAL FORM
2P8PA:108-211; B:114-214; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE LELDKWASLW[N-AC]
2PO6B:1-99; C:1-116; G:1-116; D:2-118; H:2-118; D:119-244; H:119-244; A:183-280; E:183-277; F:2-99CRYSTAL STRUCTURE OF CD1D-LIPID-ANTIGEN COMPLEXED WITH BETA-2-MICROGLOBULIN, NKT15 ALPHA-CHAIN AND NKT15 BETA-CHAIN
2PR4L:108-211; H:133-232; H:1-132; L:1-107CRYSTAL STRUCTURE OF FAB' FROM THE HIV-1 NEUTRALIZING ANTIBODY 2F5
2PUQT:6-105; T:106-209CRYSTAL STRUCTURE OF ACTIVE SITE INHIBITED COAGULATION FACTOR VIIA IN COMPLEX WITH SOLUBLE TISSUE FACTOR
2PW1A:108-211; B:114-214; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKWNSL
2PW2A:108-211; B:114-214; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKWKSL
2PYEB:0-99; A:182-270; D:0-114; E:0-112; E:113-238CRYSTAL STRUCTURES OF HIGH AFFINITY HUMAN T-CELL RECEPTORS BOUND TO PMHC REVEALNATIVE DIAGONAL BINDING GEOMETRY TCR CLONE C5C1 COMPLEXED WITH MHC
2PYFA:1-114; B:1-112; B:113-238CRYSTAL STRUCTURES OF HIGH AFFINITY HUMAN T-CELL RECEPTORS BOUND TO PMHC REVEALNATIVE DIAGONAL BINDING GEOMETRY UNBOUND TCR CLONE 5-1
2Q1EA:-1-107; B:-1-107; C:-1-107; D:-1-107ALTERED DIMER INTERFACE DECREASES STABILITY IN AN AMYLOIDOGENIC KAPPA1 BENCE JONES PROTEIN.
2Q20A:0-107; B:-1-107STRUCTURE OF THE GERMLINE VK1 O18/O8 LIGHT CHAIN VARIABLE DOMAIN HOMODIMER
2Q6WA:82-182; D:82-182; B:94-190; E:94-190THE STRUCTURE OF HLA-DRA, DRB3*0101 (DR52A) WITH BOUND PLATELET INTEGRIN PEPTIDE ASSOCIATED WITH FETAL AND NEONATAL ALLOIMMUNE THROMBOCYTOPENIA
2Q87C:5-110; A:2-108; B:5-111THE CRYSTAL STRUCTURE OF THE HUMAN IRP60 ECTODOMAIN
2QEJA:342-450; B:342-450; A:240-341; B:242-341CRYSTAL STRUCTURE OF A STAPHYLOCOCCUS AUREUS PROTEIN (SSL7) IN COMPLEX WITH FC OF HUMAN IGA1
2QL1A:338-443; A:238-337STRUCTURAL CHARACTERIZATION OF A MUTATED, ADCC-ENHANCED HUMAN FC FRAGMENT
2QQKL:109-211; H:114-220; H:1-113; L:1-108NEUROPILIN-2 A1A2B1B2 DOMAINS IN COMPLEX WITH A SEMAPHORIN-BLOCKING FAB
2QQLL:109-214; H:114-216; H:1-113; L:1-108NEUROPILIN-2 A1A2B1B2 DOMAINS IN COMPLEX WITH A SEMAPHORIN-BLOCKING FAB
2QQNL:108-211; H:114-220; H:1-113; L:1-107NEUROPILIN-1 B1 DOMAIN IN COMPLEX WITH A VEGF-BLOCKING FAB
2QR0A:109-211; B:114-213; F:114-213; H:114-213; L:114-213; N:114-213; R:114-213; T:114-213; X:114-213; B:1-113; F:1-113; H:1-113; L:1-113; N:1-113; R:1-113; T:1-113; X:1-113; E:109-211; G:109-211; K:109-211; M:109-211; Q:109-211; S:109-211; W:109-211; A:1-108; E:1-108; G:1-108; K:1-108; M:1-108; Q:1-108; S:1-108; W:1-108STRUCTURE OF VEGF COMPLEXED TO A FAB CONTAINING TYR AND SER IN THE CDRS
2QSCL:108-211; H:114-226; H:1-113; L:1-107CRYSTAL STRUCTURE ANALYSIS OF ANTI-HIV-1 V3-FAB F425-B4E8 IN COMPLEX WITH A V3-PEPTIDE
2QSQB:1-108; A:1-110CRYSTAL STRUCTURE OF THE N-TERMINAL DOMAIN OF CARCINOEMBRYONIC ANTIGEN (CEA)
2QSTA:1-110; B:1-110CRYSTAL STRUCTURE OF THE V39C MUTANT OF THE N-TERMINAL DOMAIN OF CARCINOEMBRYONIC ANTIGEN (CEA)
2R0KL:109-214; H:114-216; H:1-113; L:1-108PROTEASE DOMAIN OF HGFA WITH INHIBITOR FAB58
2R4RL:109-211; H:115-217; H:1-114; L:1-108CRYSTAL STRUCTURE OF THE HUMAN BETA2 ADRENOCEPTOR
2R4SL:109-211; H:115-217; H:1-114; L:1-108CRYSTAL STRUCTURE OF THE HUMAN BETA2 ADRENOCEPTOR
2RB8A:801-893HIGH RESOLUTION DESIGN OF A PROTEIN LOOP
2RFXB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*5701, PRESENTING THE SELF PEPTIDE, LSSPVTKSF
2RHEA:1-114STRUCTURE OF A NOVEL BENCE-JONES PROTEIN (RHE) FRAGMENT AT 1.6 ANGSTROMS RESOLUTION
2RQ8A:0-97SOLUTION NMR STRUCTURE OF TITIN I27 DOMAIN MUTANT
2SEBA:82-180; B:92-190X-RAY CRYSTAL STRUCTURE OF HLA-DR4 COMPLEXED WITH A PEPTIDE FROM HUMAN COLLAGEN II
2UWEB:0-99; A:182-270; H:182-270; F:3-117; M:3-117; I:0-99; F:118-245; M:118-245; E:1-116; L:1-116LARGE CDR3A LOOP ALTERATION AS A FUNCTION OF MHC MUTATION
2UZIL:4-107; H:1-114CRYSTAL STRUCTURE OF HRAS(G12V) - ANTI-RAS FV COMPLEX
2V17L:109-211; H:124-222; H:1-123; L:1-108STRUCTURE OF THE COMPLEX OF ANTIBODY MN423 WITH A FRAGMENT OF TAU PROTEIN
2V2WB:0-99; E:0-99; A:182-270; D:182-270T CELL CROSS-REACTIVITY AND CONFORMATIONAL CHANGES DURING TCR ENGAGEMENT
2V2XB:0-99; E:0-99; A:182-270; D:182-270T CELL CROSS-REACTIVITY AND CONFORMATIONAL CHANGES DURING TCR ENGAGEMENT.
2V44  [entry was replaced by entry 2XY2 without any CATH domain information]
2VAJA:1-93CRYSTAL STRUCTURE OF NCAM2 IG1 (I4122 CELL UNIT)
2VB5A:0-99SOLUTION STRUCTURE OF W60G MUTANT OF HUMAN BETA2-MICROGLOBULIN
2VC2L:108-211; H:120-216; H:1-119; L:1-107RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO ANTAGONIST L-739758
2VDKL:108-211; H:120-216; H:1-119; L:1-107RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE
2VDLL:108-211; H:120-216; H:1-119; L:1-107RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE
2VDML:108-211; H:120-216; H:1-119; L:1-107RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO ANTAGONIST TIROFIBAN
2VDNL:108-211; H:120-216; H:1-119; L:1-107RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO ANTAGONIST EPTIFIBATIDE
2VDOL:108-211; H:120-216; H:1-119; L:1-107INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO FIBRINOGEN GAMMA CHAIN PEPTIDE, HHLGGAKQAGDV
2VDPL:108-211; H:120-216; H:1-119; L:1-107INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO FIBRINOGEN GAMMA CHAIN PEPTIDE,LGGAKQAGDV
2VDQL:108-211; H:120-216; H:1-119; L:1-107INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO A CHIMERIC FIBRINOGEN GAMMA CHAIN PEPTIDE, HHLGGAKQRGDV
2VDRL:108-211; H:120-216; H:1-119; L:1-107INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO A CHIMERIC FIBRINOGEN GAMMA CHAIN PEPTIDE, LGGAKQRGDV
2VH5L:4-107; H:1-114CRYSTAL STRUCTURE OF HRAS(G12V) - ANTI-RAS FV (DISULFIDE FREE MUTANT) COMPLEX
2VLJB:0-99; A:182-270; D:3-111; E:5-115; E:116-244THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN
2VLKB:0-99; A:182-270; D:3-111; E:5-115; E:116-244THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN
2VLLB:0-99; E:0-99; A:182-270; D:182-270THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN
2VLMD:3-111; E:5-115; E:116-244THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN
2VLRB:0-99; A:182-270; F:182-270; D:3-111; I:3-111; E:5-115; J:5-115; G:0-99; E:116-244; J:116-244THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN
2VWEC:107-210; E:114-212; L:114-212; J:107-210; E:1-113; L:1-113; C:1-106A; J:1-106ACRYSTAL STRUCTURE OF VASCULAR ENDOTHELIAL GROWTH FACTOR-B IN COMPLEX WITH A NEUTRALIZING ANTIBODY FAB FRAGMENT
2VXSI:114-216; K:114-215; H:114-216; J:114-213; O:109-209; H:1-113; I:1-113; J:1-113; K:1-113STRUCTURE OF IL-17A IN COMPLEX WITH A POTENT, FULLY HUMAN NEUTRALISING ANTIBODY
2VXVL:109-211; H:114-214; H:1-113CRYSTAL STRUCTURE OF HUMAN IGG ABT-325 FAB FRAGMENT
2VYRG:1-123; E:1-124; F:1-124; I:1-124; J:1-124; K:1-124; L:1-124; H:1-125STRUCTURE OF HUMAN MDM4 N-TERMINAL DOMAIN BOUND TO A SINGLE DOMAIN ANTIBODY
2W9EL:108-210; H:117-215; H:1-116STRUCTURE OF ICSM 18 (ANTI-PRP THERAPEUTIC ANTIBODY) FAB FRAGMENT COMPLEXED WITH HUMAN PRP FRAGMENT 119-231
2WAHA:338-444; B:338-445; B:237-337; A:238-337CRYSTAL STRUCTURE OF AN IGG1 FC GLYCOFORM (MAN9GLCNAC2)
2WBJC:8-112; G:10-112; A:82-180; E:82-180; H:142-268; D:142-269; F:92-190; B:92-188; H:1-141; D:-1-141TCR COMPLEX
2WIMA:19-112; B:19-112; A:113-208; B:113-208; A:209-298; B:209-294CRYSTAL STRUCTURE OF NCAM2 IG1-3
2WUBL:109-214; H:114-217; R:114-209; H:1-113; R:1-113; Q:109-214CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC NON-INHIBITORY ANTIBODY FAB40.DELTATRP
2WUCL:109-214; H:114-217; H:1-113CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC NON-INHIBITORY ANTIBODY FAB40.DELTATRP AND AC-KQLR-CHLOROMETHYLKETONE
2X4NB:0-99; A:182-270; D:181-269; E:0-99CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO RESIDUAL FRAGMENTS OF A PHOTOCLEAVABLE PEPTIDE THAT IS CLEAVED UPON UV-LIGHT TREATMENT
2X4OB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO HIV-1 ENVELOPE PEPTIDE ENV120-128
2X4PB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO A PHOTOCLEAVABLE PEPTIDE
2X4QB:1-98; A:182-270; D:182-270; E:1-98CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO A PHOTOCLEAVABLE PEPTIDE
2X4RB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO CYTOMEGALOVIRUS (CMV) PP65 EPITOPE
2X4SB:1-98; A:182-270; D:182-270; E:1-98CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO A PEPTIDE REPRESENTING THE EPITOPE OF THE H5N1 (AVIAN FLU) NUCLEOPROTEIN
2X4TB:1-98; A:182-270; D:182-270; E:1-98CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO A PEIODATE-CLEAVABLE PEPTIDE
2X4UB:0-99; A:182-270; D:182-270; E:0-99CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO HIV-1 PEPTIDE RT468-476
2XACC:129-226; X:132-226STRUCTURAL INSIGHTS INTO THE BINDING OF VEGF-B BY VEGFR-1D2: RECOGNITION AND SPECIFICITY
2YR3A:1-99SOLUTION STRUCTURE OF THE FOURTH IG-LIKE DOMAIN FROM MYOSIN LIGHT CHAIN KINASE, SMOOTH MUSCLE
2YSSA:1-107; B:1-113CRYSTAL STRUCTURE OF HUMANIZED HYHEL-10 FV MUTANT(HQ39KW47Y)-HEN LYSOZYME COMPLEX
2YXFA:0-98THE HIGH RESOLUTION CRYSTAL STRUCTURE OF BETA2-MICROGLOBULIN UNDER PHYSIOLOGICAL CONDITIONS
2Z9TA:0-99CRYSTAL STRUCTURE OF THE HUMAN BETA-2 MICROGLOBULIN MUTANT W60G
2ZCHL:109-211; L:1-108; H:114-212; H:1-113CRYSTAL STRUCTURE OF HUMAN PROSTATE SPECIFIC ANTIGEN COMPLEXED WITH AN ACTIVATING ANTIBODY
2ZCKL:109-214; L:1-108; H:114-212; H:1-113CRYSTAL STRUCTURE OF A TERNARY COMPLEX BETWEEN PSA, A SUBSTRAT-ACYL INTERMEDIATE AND AN ACTIVATING ANTIBODY
2ZCLL:109-214; L:1-108; H:114-212; H:1-113CRYSTAL STRUCTURE OF HUMAN PROSTATE SPECIFIC ANTIGEN COMPLEXED WITH AN ACTIVATING ANTIBODY
2ZKHL:108-209; H:117-205; H:1-116HUMAN THROMBOPOIETIN NEUTRALIZING ANTIBODY TN1 FAB
2ZP0T:6-105; T:106-210HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH BENZYLSULFONAMIDE-D-ILE-GLN-P-AMINOBENZAMIDINE
2ZWLT:6-105; T:106-210HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH HIGHLY SELECTIVE PEPTIDE INHIBITOR
2ZZUT:6-105; T:106-210HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5-(3-CARBOXYBENZYLOXY)-TRP-GLN-P-AMINOBENZAMIDINE
3AAZB:113-216; A:126-224; H:126-224; A:1-125; H:1-125; L:113-216CRYSTAL STRUCTURE OF THE HUMANIZED RECOMBINANT FAB FRAGMENT OF A MURINE; ANTIBODY
3B2UD:109-211; D:1-108; G:1-108; K:1-108; L:1-108; O:1-108; R:1-108; U:1-108; X:1-108; H:122-219; J:122-219; N:122-219; Q:122-219; F:122-219; T:122-219; W:122-219; C:122-219; C:1-121; F:1-121; H:1-121; J:1-121; N:1-121; Q:1-121; T:1-121; W:1-121; G:109-211; K:109-211; L:109-211; O:109-211; R:109-211; U:109-211; X:109-211CRYSTAL STRUCTURE OF ISOLATED DOMAIN III OF THE EXTRACELLULAR REGION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN COMPLEX WITH THE FAB FRAGMENT OF IMC-11F8
3B2VL:109-211; L:1-108; H:122-220; H:1-121CRYSTAL STRUCTURE OF THE EXTRACELLULAR REGION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN COMPLEX WITH THE FAB FRAGMENT OF IMC-11F8
3B3IB:0-99; A:182-276CITRULLINATION-DEPENDENT DIFFERENTIAL PRESENTATION OF A SELF-PEPTIDE BY HLA-B27 SUBTYPES
3B5GA:1-111; B:1-111CRYSTAL STRUCTURE OF THE UNSTABLE AND HIGHLY FIBRILLOGENIC PRO7SER MUTANT OF THE RECOMBINANT VARIABLE DOMAIN 6AJL2
3B6SB:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE CITRULLINATED VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408)
3B9VB:1-112; D:1-112; A:1-112; C:1-112CRYSTAL STRUCTURE OF AN AUTONOMOUS VH DOMAIN
3BDXA:1-111; B:1-111; C:1-111CRYSTAL STRUCTURE OF THE UNSTABLE AND HIGHLY FIBRILLOGENIC PRO7SER MUTANT OF THE RECOMBINANT VARIABLE DOMAIN 6AJL2
3BDYL:109-213; H:116-215; H:0-115; L:1-108DUAL SPECIFIC BH1 FAB IN COMPLEX WITH VEGF
3BE1L:109-212; H:116-215; H:1-115; L:1-108DUAL SPECIFIC BH1 FAB IN COMPLEX WITH THE EXTRACELLULAR DOMAIN OF HER2/ERBB-2
3BFOA:225-309; B:225-309; C:225-309; D:225-309CRYSTAL STRUCTURE OF IG-LIKE C2-TYPE 2 DOMAIN OF THE HUMAN MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA TRANSLOCATION PROTEIN 1
3BGMB:0-99; A:182-270CRYSTAL STRUCTURE OF PKD2 PHOSPHOPEPTIDE BOUND TO HUMAN CLASS I MHC HLA-A2
3BH8B:0-99; A:182-270CRYSTAL STRUCTURE OF RQA_M PHOSPHOPEPTIDE BOUND TO HUMAN CLASS I MHC HLA-A2
3BH9B:0-99; A:182-270CRYSTAL STRUCTURE OF RTY PHOSPHOPEPTIDE BOUND TO HUMAN CLASS I MHC HLA-A2
3BHBB:2-99; A:182-270CRYSTAL STRUCTURE OF KMD PHOSPHOPEPTIDE BOUND TO HUMAN CLASS I MHC HLA-A2
3BIKB:33-148; C:30-147CRYSTAL STRUCTURE OF THE PD-1/PD-L1 COMPLEX
3BJ91:3-118CRYSTAL STRUCTURE OF THE SURROGATE LIGHT CHAIN VARIABLE DOMAIN VPREBJ
3BJLA:2-111; B:2-111; A:112-212; B:112-212LOC, A LAMBDA 1 TYPE LIGHT-CHAIN DIMER (BENCE-JONES PROTEIN) CRYSTALLIZED IN AMMONIUM SULFATE
3BN3B:87-196CRYSTAL STRUCTURE OF ICAM-5 IN COMPLEX WITH AL I DOMAIN
3BN9E:108-211; F:114-213; D:114-213; D:1-113; F:1-113; C:108-210; C:1-107; E:1-107CRYSTAL STRUCTURE OF MT-SP1 IN COMPLEX WITH FAB INHIBITOR E2
3BO8B:0-99; A:182-274THE HIGH RESOLUTION CRYSTAL STRUCTURE OF HLA-A1 COMPLEXED WITH THE MAGE-A1 PEPTIDE
3BP4B:0-99; A:182-276THE HIGH RESOLUTION CRYSTAL STRUCTURE OF HLA-B*2705 IN COMPLEX WITH A CATHEPSIN A SIGNAL SEQUENCE PEPTIDE PCATA
3BP7B:0-99; A:182-276THE HIGH RESOLUTION CRYSTAL STRUCTURE OF HLA-B*2709 IN COMPLEX WITH A CATHEPSIN A SIGNAL SEQUENCE PEPTIDE, PCATA
3BPLB:-2-96; B:97-199CRYSTAL STRUCTURE OF THE IL4-IL4R-COMMON GAMMA TERNARY COMPLEX
3BPNB:0-96; B:97-198CRYSTAL STRUCTURE OF THE IL4-IL4R-IL13RA TERNARY COMPLEX
3BPOB:-1-96; B:97-196CRYSTAL STRUCTURE OF THE IL13-IL4R-IL13RA TERNARY COMPLEX
3BSZL:113-215; L:1-112; M:1-112; H:119-215; N:119-215; M:113-215; H:1-118; N:1-118CRYSTAL STRUCTURE OF THE TRANSTHYRETIN-RETINOL BINDING PROTEIN-FAB COMPLEX
3BT2L:108-210; H:115-208; H:1-114; L:1-107STRUCTURE OF UROKINASE RECEPTOR, UROKINASE AND VITRONECTIN COMPLEX
3BVNB:1-99; E:1-99; A:182-272; D:182-272HIGH RESOLUTION CRYSTAL STRUCTURE OF HLA-B*1402 IN COMPLEX WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2) OF EPSTEIN-BARR VIRUS
3BW9B:0-99; A:182-272CRYSTAL STRUCTURE OF HLA B*3508 IN COMPLEX WITH A HCMV 12-MER PEPTIDE FROM THE PP65 PROTEIN
3BWAB:0-99; A:182-272CRYSTAL STRUCTURE OF HLA B*3508 IN COMPLEX WITH A HCMV 8-MER PEPTIDE FROM THE PP65 PROTEIN
3BX7C:3-122ENGINEERED HUMAN LIPOCALIN 2 (LCN2) IN COMPLEX WITH THE EXTRACELLULAR DOMAIN OF HUMAN CTLA-4
3BXNB:1-99; A:182-272THE HIGH RESOLUTION CRYSTAL STRUCTURE OF HLA-B*1402 COMPLEXED WITH A CATHEPSIN A SIGNAL SEQUENCE PEPTIDE, PCATA
3BZEB:0-99; A:182-272; C:182-272; G:182-272; E:182-272; D:0-99; F:0-99; H:0-99THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E
3BZFB:3-99; A:182-272; C:182-272; D:3-99THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E
3C2AH:114-223; I:114-223; L:2-107; M:2-107; L:108-211; M:108-211; H:1-113; I:1-113ANTIBODY FAB FRAGMENT 447-52D IN COMPLEX WITH UG1033 PEPTIDE
3C2SA:338-443; A:238-337STRUCTURAL CHARACTERIZATION OF A HUMAN FC FRAGMENT ENGINEERED FOR LACK OF EFFECTOR FUNCTIONS
3C5JA:82-180; B:94-190CRYSTAL STRUCTURE OF HLA DR52C
3C9NB:1-99; A:182-272CRYSTAL STRUCTURE OF A SARS CORONA VIRUS DERIVED PEPTIDE BOUND TO THE HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I MOLECULE HLA-B*1501
3CAFA:154-249CRYSTAL STRUCTURE OF HFGFR2 D2 DOMAIN
3CD4A:1-98; A:99-173REFINEMENT AND ANALYSIS OF THE FIRST TWO DOMAINS OF HUMAN CD4
3CDGB:0-99; A:182-272; C:182-272; D:0-99HUMAN CD94/NKG2A IN COMPLEX WITH HLA-E
3CDYA:0-107; B:0-107AL-09 H87Y, IMMUNOGLOBULIN LIGHT CHAIN VARIABLE DOMAIN
3CIQG:0-98; A:0-97; B:0-97; C:0-97; D:0-97; E:0-97; F:0-97; I:0-97; J:0-97; K:0-97; L:0-97; H:0-97A REGULATABLE SWITCH MEDIATES SELF-ASSOCIATION IN AN IMMUNOGLOBULIN FOLD
3CNKA:2559-2647; B:2559-2647CRYSTAL STRUCTURE OF THE DIMERIZATION DOMAIN OF HUMAN FILAMIN A
3CSYB:108-211; A:114-228; C:114-228; E:114-228; G:114-228; B:1-107; D:1-107; F:1-107; H:1-107; A:1-113; C:1-113; E:1-113; G:1-113; D:108-211; F:108-211; H:108-211CRYSTAL STRUCTURE OF THE TRIMERIC PREFUSION EBOLA VIRUS GLYCOPROTEIN IN COMPLEX WITH A NEUTRALIZING ANTIBODY FROM A HUMAN SURVIVOR
3CU1A:154-249; C:154-249CRYSTAL STRUCTURE OF 2:2:2 FGFR2D2:FGF1:SOS COMPLEX
3CXE  [entry was replaced by entry 4NKQ without any CATH domain information]
3D0LA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 BROADLY NEUTRALIZING ANTIBODY 2F5 IN COMPLEX WITH THE GP41 FP-MPER HYB3K CONSTRUCT 514GIGALFLGFLGAAGS528KK-AHX-655KNEQELLELDKWASLWN671
3D0VA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE LLELDKWASLW
3D18B:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH A VARIANT OF THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2(L)) OF EPSTEIN-BARR VIRUS
3D25B:2-99; A:182-270CRYSTAL STRUCTURE OF HA-1 MINOR HISTOCOMPATIBILITY ANTIGEN BOUND TO HUMAN CLASS I MHC HLA-A2
3D48R:2-101; R:102-204CRYSTAL STRUCTURE OF A PROLACTIN RECEPTOR ANTAGONIST BOUND TO THE EXTRACELLULAR DOMAIN OF THE PROLACTIN RECEPTOR
3D5OF:87-171; F:1-86STRUCTURAL RECOGNITION AND FUNCTIONAL ACTIVATION OF FCRR BY INNATE PENTRAXINS
3D6GA:338-443; B:338-443; A:238-337; B:238-337FC FRAGMENT OF IGG1 (HERCEPTIN) WITH PROTEIN-A MIMETIC PEPTIDE DENDRIMER LIGAND.
3D85A:109-213; B:116-215; B:1-115; D:103-210; D:1-84; D:214-304; A:1-108CRYSTAL STRUCTURE OF IL-23 IN COMPLEX WITH NEUTRALIZING FAB
3D87B:103-210; D:103-210; B:1-84; D:1-84; B:214-304; D:214-304CRYSTAL STRUCTURE OF INTERLEUKIN-23
3DARA:154-249; B:154-249CRYSTAL STRUCTURE OF D2 DOMAIN FROM HUMAN FGFR2
3DHJA:0-99BETA 2 MICROGLOBULIN MUTANT W60C
3DHMA:0-99BETA 2 MICROGLOBULIN MUTANT D59P
3DI2B:109-211; D:109-209CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN INTERLEUKIN-7 WITH UNGLYCOSYLATED HUMAN INTERLEUKIN-7 RECEPTOR ALPHA ECTODOMAIN
3DI3B:109-209CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN INTERLEUKIN-7 WITH GLYCOSYLATED HUMAN INTERLEUKIN-7 RECEPTOR ALPHA ECTODOMAIN
3DJ9A:236-342CRYSTAL STRUCTURE OF AN ISOLATED, UNGLYCOSYLATED ANTIBODY CH2 DOMAIN
3DROA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELLELDKWASLWN GROWN IN AMMONIUM SULFATE
3DRQA:108-211; B:114-213; B:1-113; A:1-107CRYSTAL STRUCTURE OF THE HIV-1 BROADLY NEUTRALIZING ANTIBODY 2F5 IN COMPLEX WITH THE GP41 FP-MPER HYB3K CONSTRUCT 514GIGALFLGFLGAAGS528KK-AHX-655KNEQELLELDKWASLWN671 SOAKED IN PEG/2-PROPANOL SOLUTION
3DRTA:108-211; B:114-213; B:1-113CRYSTAL STRUCTURE OF THE HIV-1 BROADLY NEUTRALIZING ANTIBODY 2F5 IN COMPLEX WITH THE GP41 SCRAMBLEDFP-MPER SCRHYB3K CONSTRUCT GIGAFGLLGFLAAGSKK-AHX-K656NEQELLELDKWASLWN671
3DTXB:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE DOUBLE CITRULLINATED VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408)
3DUHB:103-210; A:103-210; B:-1-84; A:0-84; A:214-304; B:214-304STRUCTURE OF INTERLEUKIN-23
3DVGA:111-214; B:121-221; B:1-120; A:5-110CRYSTAL STRUCTURE OF K63-SPECIFIC FAB APU.3A8 BOUND TO K63-LINKED DI-UBIQUITIN
3DVNA:111-216; B:121-221; H:121-221; B:1-120; H:1-120; L:111-216; A:5-110; L:5-110CRYSTAL STRUCTURE OF K63-SPECIFIC FAB APU2.16 BOUND TO K63-LINKED DI-UBIQUITIN
3DX6B:1-99; A:182-272CRYSTAL STRUCTURE OF B*4402 PRESENTING A 10MER EBV EPITOPE
3DX7B:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*4403 PRESENTING 10MER EBV ANTIGEN
3DX8B:1-99; A:182-272CRYSTAL STRUCTURE OF B*4405 PRESENTING A 10MER EBV EPITOPE
3DX9A:2-125; C:2-125; B:2-128; D:2-128; B:129-257; D:129-257CRYSTAL STRUCTURE OF THE DM1 TCR AT 2.75A
3DXAB:1-99; D:2-125; I:2-125; N:2-125; E:2-128; J:2-128; O:2-128; E:129-257; J:129-257; O:129-257; G:1-99; L:1-99; A:182-272; F:182-272; K:182-272CRYSTAL STRUCTURE OF THE DM1 TCR IN COMPLEX WITH HLA-B*4405 AND DECAMER EBV ANTIGEN
3EKCA:0-99STRUCTURE OF W60V BETA-2 MICROGLOBULIN MUTANT
3ELAT:6-105; T:106-209CRYSTAL STRUCTURE OF ACTIVE SITE INHIBITED COAGULATION FACTOR VIIA MUTANT IN COMPLEX WITH SOLUBLE TISSUE FACTOR
3ES6A:184-273CRYSTAL STRUCTURE OF THE NOVEL COMPLEX FORMED BETWEEN ZINC 2-GLYCOPROTEIN (ZAG) AND PROLACTIN INDUCIBLE PROTEIN (PIP) FROM HUMAN SEMINAL PLASMA
3EUUA:154-249; B:154-249CRYSTAL STRUCTURE OF THE FGFR2 D2 DOMAIN
3EW3B:0-101; C:4-101; B:102-202; C:102-201THE 1:2 COMPLEX BETWEEN A NTERMINAL ELONGATED PROLACTIN AND THE EXTRA CELLULAR DOMAIN OF THE RAT PROLACTIN RECEPTOR
3F7PC:1217-1330; C:1127-1216CRYSTAL STRUCTURE OF A COMPLEX BETWEEN INTEGRIN BETA4 AND PLECTIN
3FCTC:109-211; B:115-214; D:115-214; A:109-213; A:1-108; C:1-108; B:1-114; D:1-114MATURE METAL CHELATASE CATALYTIC ANTIBODY WITH HAPTEN
3FFCB:0-99; E:2-131; J:2-131; E:132-260; J:132-260; G:0-99; D:3-122; I:3-122; A:182-272; F:182-272CRYSTAL STRUCTURE OF CF34 TCR IN COMPLEX WITH HLA-B8/FLR
3FJTA:338-443; B:338-443; A:238-337; B:238-337CRYSTAL STRUCTURE OF A HUMAN FC FRAGMENT ENGINEERED FOR EXTENDED SERUM HALF-LIFE
3FQNB:1-98; A:182-270PHOSPHORYLATION OF SELF-PEPTIDES ALTERS HUMAN LEUKOCYTE ANTIGEN CLASS I-RESTRICTED ANTIGEN PRESENTATION AND GENERATES TUMOR SPECIFIC EPITOPES
3FQRB:1-98; A:182-270PHOSPHORYLATION OF SELF-PEPTIDES ALTERS HUMAN LEUKOCYTE ANTIGEN CLASS I-RESTRICTED ANTIGEN PRESENTATION AND GENERATES TUMOR SPECIFIC EPITOPES
3FQTB:1-98; A:182-270PHOSPHORYLATION OF SELF-PEPTIDES ALTERS HUMAN LEUKOCYTE ANTIGEN CLASS I-RESTRICTED ANTIGEN PRESENTATION AND GENERATES TUMOR SPECIFIC EPITOPES
3FQUB:1-98; A:182-270PHOSPHORYLATION OF SELF-PEPTIDES ALTERS HUMAN LEUKOCYTE ANTIGEN CLASS I-RESTRICTED ANTIGEN PRESENTATION AND GENERATES TUMOR SPECIFIC EPITOPES
3FQWB:1-98; A:182-270PHOSPHORYLATION OF SELF-PEPTIDES ALTERS HUMAN LEUKOCYTE ANTIGEN CLASS I-RESTRICTED ANTIGEN PRESENTATION AND GENERATES TUMOR SPECIFIC EPITOPES
3FQXB:1-98; A:182-270PHOSPHORYLATION OF SELF-PEPTIDES ALTERS HUMAN LEUKOCYTE ANTIGEN CLASS I-RESTRICTED ANTIGEN PRESENTATION AND GENERATES TUMOR SPECIFIC EPITOPES
3FT2B:0-99; A:182-270CRYSTAL STRUCTURE OF A CITRULLINE PEPTIDE VARIANT OF THE MINOR HISTOCOMPATIBILITY PEPTIDE HA-1 IN COMPLEX WITH HLA-A2
3FT3B:0-99; A:182-270CRYSTAL STRUCTURE OF THE MINOR HISTOCOMPATIBILITY PEPTIDE HA-1HIS IN COMPLEX WITH HLA-A2
3FT4B:0-99; A:182-270CRYSTAL STRUCTURE OF THE MINOR HISTOCOMPATIBILITY PEPTIDE HA-1ARG IN COMPLEX WITH HLA-A2
3FZUD:108-211; H:119-219; C:119-219; C:1-118; H:1-118; L:108-211IGG1 FAB CHARACTERIZED BY H/D EXCHANGE
3G04B:114-213; B:1-113; A:108-208CRYSTAL STRUCTURE OF THE TSH RECEPTOR IN COMPLEX WITH A THYROID-STIMULATING AUTOANTIBODY
3G6AB:123-222; H:123-222; B:1-122; H:1-122CRYSTAL STRUCTURE OF ANTI-IL-13 ANTIBODY CNTO607
3G6DH:123-223; H:1-122CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN CNTO607 FAB AND IL-13
3G6JE:109-214; F:114-213; H:114-213; F:1-113; H:1-113; G:109-214C3B IN COMPLEX WITH A C3B SPECIFIC FAB
3GHBH:114-211; I:114-211; H:1-113; I:1-113CRYSTAL STRUCTURE OF ANTI-HIV-1 FAB 447-52D IN COMPLEX WITH V3 PEPTIDE W2RW020
3GHEH:114-211; H:1-113CRYSTAL STRUCTURE OF ANTI-HIV-1 FAB 537-10D IN COMPLEX WITH V3 PEPTIDE MN
3GIVB:0-99; A:182-270; D:182-270; E:0-99ANTIGEN PROCESSING INFLUENCES HIV-SPECIFIC CYTOTOXIC T LYMPHOCYTE IMMUNODOMINANCE
3GIZL:109-211; H:123-222; H:1-122CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF ANTI-CD20 ANTIBODY OFATUMUMAB
3GJEB:120-219; H:120-219; B:1-119; H:1-119RATIONAL DEVELOPMENT OF HIGH-AFFINITY T-CELL RECEPTOR-LIKE ANTIBODIES
3GJFB:0-99; A:182-270; D:182-270; H:120-219; M:120-219; H:1-119; M:1-119; E:0-99RATIONAL DEVELOPMENT OF HIGH-AFFINITY T-CELL RECEPTOR-LIKE ANTIBODIES
3GKWL:109-207; H:108-212; H:6-107CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF NIMOTUZUMAB. AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY
3GRWL:109-214; H:114-216; H:1-113FGFR3 IN COMPLEX WITH A FAB
3GSNL:0-99; H:182-270CRYSTAL STRUCTURE OF THE PUBLIC RA14 TCR IN COMPLEX WITH THE HCMV DOMINANT NLV/HLA-A2 EPITOPE
3GSOB:0-99; A:182-270CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV PEPTIDE
3GSQB:0-99; A:182-270CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-M5S PEPTIDE VARIANT
3GSRB:0-99; A:182-270CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-M5V PEPTIDE VARIANT
3GSUB:0-99; A:182-270CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-M5T PEPTIDE VARIANT
3GSVB:0-99; A:182-270CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-M5Q PEPTIDE VARIANT
3GSWB:0-99; A:182-270CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-T8A PEPTIDE VARIANT
3GSXB:0-99; A:182-270CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-T8V PEPTIDE VARIANT
3H0TB:123-220; B:1-122HEPCIDIN-FAB COMPLEX
3H3BC:138-244; D:138-244CRYSTAL STRUCTURE OF THE SINGLE-CHAIN FV (SCFV) FRAGMENT OF AN ANTI-ERBB2 ANTIBODY CHA21 IN COMPLEX WITH RESIDUES 1-192 OF ERBB2 EXTRACELLULAR DOMAIN
3H42H:124-224; H:1-123CRYSTAL STRUCTURE OF PCSK9 IN COMPLEX WITH FAB FROM LDLR COMPETITIVE ANTIBODY
3H7BB:0-99; E:0-99; A:182-270; D:182-270HUMAN CLASS I MHC HLA-A2 IN COMPLEX WITH THE TEL1P PEPTIDE
3H8NA:103-200; A:6-102CRYSTAL STRUCTURE ANALYSIS OF KIR2DS4
3H9HB:0-99; D:182-270; A:183-270; E:0-99HUMAN CLASS I MHC HLA-A2(A150P) IN COMPLEX WITH THE TEL1P PEPTIDE
3H9SB:0-99; A:182-270; D:1-116THE COMPLEX BETWEEN TCR A6 AND HUMAN CLASS I MHC HLA-A2 WITH THE BOUND TEL1P PEPTIDE
3H9YA:436-543; B:436-543; E:436-543; B:335-435; A:336-435; E:336-435CRYSTAL STRUCTURE OF THE IGE-FC3-4 DOMAINS
3H9ZA:436-543; B:436-543; C:436-543; D:436-543; A:336-435; B:336-435; C:336-435; D:336-435CRYSTAL STRUCTURE OF THE IGE-FC3-4 DOMAINS
3HA0A:436-543; B:436-543; C:436-543; D:436-543; E:436-543; F:436-543; A:336-435; B:336-435; C:336-435; D:336-435; E:336-435; F:336-435CRYSTAL STRUCTURE OF THE IGE-FC3-4 DOMAINS
3HAEB:0-99; A:182-270; D:182-270; J:182-270; P:182-270; H:120-219; I:120-219; O:120-219; T:120-219; G:111-211; L:111-211; N:111-211; S:111-211; H:1-119; I:1-119; O:1-119; T:1-119; E:0-99; K:0-99; Q:0-99RATIONAL DEVELOPMENT OF HIGH-AFFINITY T-CELL RECEPTOR-LIKE ANTIBODIES
3HC0B:109-211; H:117-217; A:117-216; A:1-116; H:1-116; L:109-211BHA10 IGG1 WILD-TYPE FAB - ANTIBODY DIRECTED AT HUMAN LTBR
3HC3L:109-211; H:117-217; H:1-116BHA10 IGG1 FAB DOUBLE MUTANT VARIANT - ANTIBODY DIRECTED AT HUMAN LTBR
3HC4L:109-211; H:117-217; H:1-116BHA10 IGG1 FAB QUADRUPLE MUTANT VARIANT - ANTIBODY DIRECTED AT HUMAN LTBR
3HCVB:0-99; A:182-276CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE DOUBLE CITRULLINATED VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408)
3HG1B:0-99; A:182-270; D:2-109GERMLINE-GOVERNED RECOGNITION OF A CANCER EPITOPE BY AN IMMUNODOMINANT HUMAN T CELL RECEPTOR
3HHRB:132-234; C:132-232; B:32-131; C:32-131HUMAN GROWTH HORMONE AND EXTRACELLULAR DOMAIN OF ITS RECEPTOR: CRYSTAL STRUCTURE OF THE COMPLEX
3HI5L:107-210; H:121-220; H:2-120CRYSTAL STRUCTURE OF FAB FRAGMENT OF AL-57
3HI6L:107-210; X:121-220; H:121-220; H:1-120; X:1-120; Y:107-210CRYSTAL STRUCTURE OF INTERMEDIATE AFFINITY I DOMAIN OF INTEGRIN LFA-1 WITH THE FAB FRAGMENT OF ITS ANTIBODY AL-57
3HLAB:1-99; A:182-270HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN A2.1
3HMWL:108-214; H:120-221; H:1-119CRYSTAL STRUCTURE OF USTEKINUMAB FAB
3HMXL:108-214; H:120-220; H:1-119; A:103-210; A:1-84; A:214-304CRYSTAL STRUCTURE OF USTEKINUMAB FAB/IL-12 COMPLEX
3HUJD:1-99; E:1-116; G:1-116; B:1-97; A:183-280; C:183-278CRYSTAL STRUCTURE OF HUMAN CD1D-ALPHA-GALACTOSYLCERAMIDE IN COMPLEX WITH SEMI-INVARIANT NKT CELL RECEPTOR
3I6GB:0-99; A:182-270; D:182-270; E:0-99NEWLY IDENTIFIED EPITOPE MN2 FROM SARS-COV M PROTEIN COMPLEXED WITHHLA-A*0201
3I6KB:0-99; A:182-270; E:182-270; F:0-99NEWLY IDENTIFIED EPITOPE FROM SARS-COV MEMBRANE PROTEIN COMPLEXED WITH HLA-A*0201
3IXAB:0-99; A:183-270; D:183-270; E:0-99HUMAN CLASS I MHC HLA-A2(A150P) IN COMPLEX WITH THE TAX PEPTIDE
3JUYA:1-126; C:1-127; D:1-127; E:1-127; F:1-127; B:1-130CRYSTAL STRUCTURE OF A 3B3 VARIANT, A BROADLY NEUTRALIZING HIV-1 SCFV ANTIBODY
3K2MC:1-101; D:1-101CRYSTAL STRUCTURE OF MONOBODY HA4/ABL1 SH2 DOMAIN COMPLEX
3K2UL:109-214; H:114-216; H:1-113CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC INHIBITORY ANTIBODY FAB40
3KJ6L:109-211; H:115-217; H:1-114CRYSTAL STRUCTURE OF A METHYLATED BETA2 ADRENERGIC RECEPTOR-FAB COMPLEX
3KLAB:0-99; E:0-99; A:182-270; D:182-270CA2+ RELEASE FROM THE ENDOPLASMIC RETICULUM OF NY-ESO-1 SPECIFIC T CELLS IS MODULATED BY THE AFFINITY OF T CELL RECEPTOR AND BY THE USE OF THE CD8 CO-RECEPTOR
3KPLB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA B*4402 IN COMPLEX WITH EEYLQAFTY A SELF PEPTIDE FROM THE ABCD3 PROTEIN
3KPMB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA B*4402 IN COMPLEX WITH EEYLKAWTF, A MIMOTOPE
3KPNB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA B*4403 IN COMPLEX WITH EEYLQAFTY A SELF PEPTIDE FROM THE ABCD3 PROTEIN
3KPOB:0-99; A:182-272CRYSTAL STRUCTURE OF HLA B*4403 IN COMPLEX WITH EEYLKAWTF, A MIMOTOPE
3KPPB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA B*4405 IN COMPLEX WITH EEYLQAFTY A SELF PEPTIDE FROM THE ABCD3 PROTEIN
3KPQB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA B*4405 IN COMPLEX WITH EEYLKAWTF, A MIMOTOPE
3KPRB:1-99; D:2-116; I:2-116; G:1-99; A:182-272; F:182-272CRYSTAL STRUCTURE OF THE LC13 TCR IN COMPLEX WITH HLA B*4405 BOUND TO EEYLKAWTF A MIMOTOPE
3KPSB:1-99; D:2-116; A:182-272CRYSTAL STRUCTURE OF THE LC13 TCR IN COMPLEX WITH HLA B*4405 BOUND TO EEYLQAFTY A SELF PEPTIDE FROM THE ABCD3 PROTEIN
3KR3L:109-212; H:123-222; H:1-122CRYSTAL STRUCTURE OF IGF-II ANTIBODY COMPLEX
3KWWB:1-99; A:182-272CRYSTAL STRUCTURE OF THE 'RESTRICTION TRIAD' MUTANT OF HLA B*3508, BETA-2-MICROGLOBULIN AND EBV PEPTIDE
3KXFB:1-99; F:1-99; J:1-99; L:1-99; D:1-114; G:1-114; M:1-114; N:1-114; A:182-272; C:182-272; I:182-272; K:182-272CRYSTAL STRUCTURE OF SB27 TCR IN COMPLEX WITH THE 'RESTRICTION TRIAD' MUTANT HLA-B*3508-13MER
3KYKL:109-211; H:120-220; H:1-119CRYSTAL STRUCTURE OF LI33 IGG1 FAB
3KYNB:0-99; A:182-272CRYSTAL STRUCTURE OF HLA-G PRESENTING KGPPAALTL PEPTIDE
3KYOB:0-99; A:182-272; C:182-272; D:0-99CRYSTAL STRUCTURE OF HLA-G PRESENTING KLPAQFYIL PEPTIDE
3L3DB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*4402 IN COMPLEX WITH THE F3A MUTANT OF A SELF-PEPTIDE DERIVED FROM DPA*0201
3L3GB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*4402 IN COMPLEX WITH THE R5A MUTANT OF A SELF-PEPTIDE DERIVED FROM DPA*0201
3L3IB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*4402 IN COMPLEX WITH THE F7A MUTANT OF A SELF-PEPTIDE DERIVED FROM DPA*0201
3L3JB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*4402 IN COMPLEX WITH THE F3A/R5A DOUBLE MUTANT OF A SELF-PEPTIDE DERIVED FROM DPA*0201
3L3KB:1-99; A:182-272CRYSTAL STRUCTURE OF HLA-B*4402 IN COMPLEX WITH THE R5A/F7A DOUBLE MUTANT OF A SELF-PEPTIDE DERIVED FROM DPA*0201
3L5XL:109-214; H:122-220; H:2-121CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN IL-13 AND H2L6 FAB
3L5Y  [entry was replaced by entry 4PS4 without any CATH domain information]
3L6FA:82-180; B:93-190STRUCTURE OF MHC CLASS II MOLECULE HLA-DR1 COMPLEXED WITH PHOSPHOPEPTIDE MART-1
3LVEA:1-108LEN Q38E MUTANT: A DOMAIN FLIP FROM A SINGLE AMINO ACID SUBSTITUTION
3MCG1:2-111; 2:2-111; 1:112-216; 2:112-212THREE-DIMENSIONAL STRUCTURE OF A LIGHT CHAIN DIMER CRYSTALLIZED IN WATER. CONFORMATIONAL FLEXIBILITY OF A MOLECULE IN TWO CRYSTAL FORMS
4BJLA:2-111; B:2-111; A:112-212; B:112-210LOCW, A LAMBDA 1 TYPE LIGHT-CHAIN DIMER (BENCE-JONES PROTEIN) CRYSTALLIZED IN DISTILLED WATER
4LVEB:301-407; A:1-108LEN K30T MUTANT: A DOMAIN FLIP AS A RESULT OF A SINGLE AMINO ACID SUBSTITUTION
5LVEA:1-108STRUCTURE OF THE VARIABLE DOMAIN OF HUMAN IMMUNOGLOBULIN K-4 LIGHT CHAIN LEN
7FABH:118-216; L:1-103; H:1-117; L:104-204CRYSTAL STRUCTURE OF HUMAN IMMUNOGLOBULIN FRAGMENT FAB NEW REFINED AT 2.0 ANGSTROMS RESOLUTION
8FABD:122-221; B:122-222; A:3-107; C:3-107; A:108-208; C:108-208; B:1-121; D:1-121CRYSTAL STRUCTURE OF THE FAB FRAGMENT FROM THE HUMAN MYELOMA IMMUNOGLOBULIN IGG HIL AT 1.8 ANGSTROMS RESOLUTION